

AWARD NUMBER: W81XWH-17-1-0137

TITLE: Defining the Consequence of CHD1 Loss on Transcriptional Regulation and Therapeutic Response

PRINCIPAL INVESTIGATOR: Michael A. Augello

CONTRACTING ORGANIZATION: Joan & Sanford I Weill Medical College of Cornell University
New York, NY 10021

REPORT DATE: Sept 2019

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE Sept 2019		2. REPORT TYPE Final Report		3. DATES COVERED 1 Jun 2017 - 31 May 2019	
4. TITLE AND SUBTITLE Defining the consequence of CHD1 loss on transcriptional regulation and therapeutic response				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-17-1-0137	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Augello M E-Mail: mia2025@med.cornell.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Weill Cornell Medical College 1300 York Ave New York NY 10065				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT -Genome wide studies have identified a high prevalence of inactivating genomic alterations associated with nucleosome remodeling and modifying enzymes, suggesting that deregulation of chromatin architecture is critical in tumor initiation/progression. CHD1 is a founding member of the chromatin remodeling family, characterized by tandem Chromo-domains, a DNA Helicase domain, and DNA binding domain (CHD1). A multitude of studies have demonstrated that CHD1 is recruited to the promoters of highly transcribed genes by the epigenetic mark H3K4me3, where it redistributes local nucleosomes ahead of RNA polymerase to facilitate efficient transcriptional initiation and RNA processing. While a majority of cell types appear to be dependent upon the function of CHD1, a subclass of primary PCa is characterized by the genomic loss of this chromatin remodeler. Given that PCa is a disease driven by aberrant transcriptional regulation mediated by oncogenic transcriptional factors (e.g. AR and MYC), it is imperative to understand the molecular underpinnings of CHD1 loss in driving these oncogenic programs. For the first time, our preliminary data demonstrate that in a prostate-specific background, CHD1 localizes to enhancer-like regions of the genome specifically occupied by AR and its associated transcriptional regulators (FOXA1 and HOXB13). This CHD1 binding signature is highly consistent with epigenetic marks identifying these enhancer sites, suggesting that CHD1 remodels enhancer-like chromatin to define a unique AR cistrome. Furthermore, CHD1 was found to be dispensable for global transcriptional output in prostate derived models, but was essential for efficient transcriptional processing. Thus, loss of CHD1 may have a global impact on the AR transcriptional network, deregulating both genomic binding and resultant transcriptional output, via distinct molecular mechanisms.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 33	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	2
2. Keywords.....	2
3. Accomplishments.....	3-7
4. Impact.....	7-8
5. Changes/Problems.....	8
6. Products.....	8
7. Participants & Other Collaborating Organizations.....	8
8. Special Reporting Requirements.....	N/A
9. Appendices.....	9-33

1: Introduction

PCa is highly dependent upon the action of the androgen receptor (AR), the protein responsible for prostate cell growth and survival at all stages of disease. AR is a transcription factor that is activated by binding to androgens (e.g. testosterone). Activation results in AR binding to DNA where it induces the expression of a specific set of target genes required for prostate development and growth. Importantly, a critical step in the process of prostate tumorigenesis is the rewiring of AR, wherein AR is redirected away from its normal target genes, and instead promotes the expression of genes associated with tumor growth and survival. One well established mechanism for this reprogramming can be seen in the ERG-fusion positive subclass of prostate cancer, which inappropriately expresses the transcription factor ERG. In this context, ERG can physically bind to DNA and AR and direct it to novel sites on DNA, where it forces AR to promote expression of pro-oncogenic genes unique to this subclass of PCa. This signature has been established in a multitude of clinical samples and is distinct from all other subtypes of PCa, including those characterized by CHD1 loss. Thus, while ERG induction has been established as a key event in the rewiring of AR during tumor formation, the mechanisms that alter AR binding in the other subtypes remains unclear.

One such subclass is characterized by the deletion of a specific gene on chromosome 5 called CHD1. It belongs to a family of genes whose primary function is to open up DNA to allow for essential proteins to bind and promote gene expression. Several studies have demonstrated that CHD1 is recruited to genes that are highly expressed and is required to maintain cell survival and growth. Interestingly however, our preliminary data suggests that CHD1 functions differently in a prostate specific setting. For the first time, we demonstrate that in a prostate specific background, 1) CHD1 directs where AR binds to DNA, 2) Cells which lack CHD1 still require AR for growth and survival, 3) Loss of CHD1 does not decrease cell growth or survival, and 4) CHD1 binds to many proteins known to regulate AR function. We thus hypothesize that loss of CHD1 represents a specific mechanism through which AR is reprogrammed to promote tumor formation and growth. Given that the clinical signatures of this subtype of cancer are very distinct from the others, it is likely that identification of the genes that AR regulates in CHD1 deficient tumors will nominate novel pathways that can be targeted to limit growth of this aggressive tumor class.

2: Keywords

- Prostate Cancer
- Androgen Receptor
- CHD1
- Epigenetics
- HOXB13
- Tumor Cistrome
- Prostate Cancer Subclass
- ChIP Sequencing
- AR
- AR signaling
- Tumor Suppressor

3: Accomplishments

Goals:

Overarching goals	Timeline (Months)	Status
AIM 1: Define the Chromatin Landscape upon CHD1 deletion	1-18	Completed
Generation of cell models	1-3	Completed
ATAC Seq of CHD1 null models	3-5	Completed
ChIP Sequencing of CHD1 null models	6-9	Completed
AR RIME of CHD1 null models	6-9	Completed
Analysis of Sequencing data-	10-18	Completed
AIM 2: Describe the impact on transcriptional regulation and tumor biology upon chd1 loss	6-24	Completed
RNA Seq in CHD1 null models	6-10	Completed
Analysis of RNA Sequencing	11-18	Completed
Correlation with Clinical Data	18-24	Completed
Identify pathways critical for CHD1 null models	12-16	Completed
Assessment of CHD1 null tumor phenotypes	16-24	Completed
AIM 3: Define CHD1 status as a predictor of therapeutic response	4-24	Completed
Assessment of CHD1 loss in response to current therapeutic options	4-12	Completed
Novel Drug Screen in CHD1 null models	12-24	Completed

Accomplishments: This project has been successfully completed and the results have recently been published in the April 15th edition of “*Cancer Cell*” -

Cancer Cell
Article



CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

Michael A. Augello,^{1,2} Deli Liu,^{1,2,3} Lesa D. Deonaraine,^{1,2} Brian D. Robinson,^{4,5} Dennis Huang,^{1,2} Suzan Stelloo,⁶ Mirjam Blattner,^{1,4} Ashley S. Doane,³ Elissa W.P. Wong,⁷ Yu Chen,^{7,8} Mark A. Rubin,^{2,4,5} Himisha Beltran,^{2,5,9} Olivier Elemento,^{3,4,5} Andries M. Bergman,^{5,10} Wilbert Zwart,^{6,11} Andrea Sboner,^{2,3,4,5} Noah Dephoure,^{2,12} and Christopher E. Barbieri^{1,2,5,13,*}

Summary of Conclusions by Aim

As this project has been completed and results published, major conclusions of each subaim will be bulleted below.

AIM 1: Consequence of CHD1 loss on global chromatin architecture and oncogenic cistromes.

*Rationale: There is compelling evidence that CHD1 functions as a potent tumor suppressor in PCa, yet the mechanisms through which this chromatin remodeler limits tumor formation remain unknown. Our preliminary data demonstrate that, in a prostate specific context, CHD1 co-localizes with critical transcriptional regulators at enhancer-like DNA, in patterns consistent with active nucleosome turnover. This suggests that CHD1 acts as a global regulator of chromatin architecture and transcription factor binding in prostate tissue. *Aim1 has built on these findings and defined the consequences of CHD1 loss on global chromatin architecture (Aim1A), the cistromes of AR and its co-factors (Aim1B), and the interactome of AR transcriptional complexes (Aim1C).**

Major Conclusions from AIM1 (As reported in Augello et. al. 2019):

ChIP Seq: CHD1 loss redistributes AR to sites across the genome enriched for HOXB13 motifs, and depleted for the canonical Androgen response elements (ARE and AR-Halfsites)

ATAC Seq: Upon androgen stimulation, a subset of enhancer sites containing the HOXB13 motif are “closed down” limiting the binding of transcriptional activation complexes in favor of “opening” ARE containing sites. However, in the absence of CHD1, this process is inhibited, stabilizing the active confirmation of HOXB13 enhancers and limiting the accessibility of sites only containing ARE’s.

RIME: The AR interactome is largely unchanged by depletion of CHD1, suggesting the impact of CHD1 loss on AR function is upstream of transcriptional complex assembly.

AIM2: Characterize the transcriptional signatures of CHD1 loss and the impact on tumor growth.

*Rationale: Our preliminary data demonstrate that, unlike other tissue types, depletion of CHD1 does not decrease total transcriptional output or reduce cell growth, consistent with its proposed role as a tumor suppressor in prostate tissue. Rather, interrogation of the prostate specific cistrome and interactome of chromatin-bound CHD1 uncovered significant enrichment of critical transcriptional regulators, suggesting the tumorigenic consequences of CHD1 loss are manifested through altered transcription factor function and target gene selection. Thus, *this aim has identified oncogenic signatures that result upon CHD1 loss and defined transcriptional networks critical to the growth and survival of CHD1 null tumors.**

Major Conclusions from AIM2 (As reported in Augello et. al. 2019):

RNA Seq: *CHD1* loss results in a divergent AR transcriptome that is distinct from *CHD1* proficient prostate cancer lines.

Clinical AR Signatures: The *CHD1* null AR signature derived from our isogenic models are highly concordant with the transcriptomes of *CHD1* null clinical tumors, and are unique to this specific subclass of primary prostate cancers.

Transcriptional Networks: AR has been shown to act as a rheostat with regards to the AKT pathway, whereby activation of AR inhibits signaling flux through AKT networks (and vice versa). However, loss of *CHD1* disrupts the ability of AR to dampen AKT activity, and thus allows for continued and sustained signaling of AR and AKT simultaneously.

Aim3: Evaluate the status of CHD1 as a predictor of therapeutic response.

Rationale: Currently, only limited therapeutic options exist for patients with metastatic PCa, with the most effective of these focused on either directly or indirectly inhibiting the AR signaling axis. While most patients respond to treatment initially, these options frequently fail, emphasizing the need for more efficacious therapeutics and a patient-tailored approach to cancer therapy. Given the high prevalence of genomic *CHD1* deletion in primary disease, and the specificity of this lesion to prostate tumors, *CHD1* loss may represent a therapeutic window to specifically target this subclass of tumors. Thus, this aim has utilized both targeted (*Aim3A*) and unbiased (*Aim3B*) approaches to evaluate the ability of *CHD1* loss to serve as a predictor of response to first line therapeutics, and nominate novel therapeutic options to limit the growth and survival of *CHD1* deficient tumors.

Major Conclusions from AIM3 (Partially reported in Augello et. al. 2019):

AR directed therapeutics: *In vitro*, there was no observed differences in the response rates of *CHD1* deficient prostate cancer lines to androgen withdrawal or enzalutamide treatment (compared to controls). However, a notable resistance of *CHD1* deficient lines to high dose androgens was noted and characterized, suggesting *CHD1* loss could be developed as a marker of resistance to this form of currently utilized therapy.

Unbiased Drug Screen: A panel of over 200 compounds were tested in this screen which utilized isogenic models of *CHD1* deficiency. Several clinically relevant hits were observed including docetaxel and Talazoparib- a novel PARPi with a unique mechanism of action. Future work will cross validate these finding across multiple *CHD1* null models and stages of disease progression.

Conclusions Years 1-2:

- Promoter specific functions of CHD1 are preserved in a prostate specific context
 - CHD1 localizes to enhancer-like chromatin enriched for AR and its cofactors
 - The enhancer-specific CHD1 interactome is enriched for AR cofactors
- Loss of CHD1 redistributes AR to sites actively occupied by HOXB13
 - The CHD1 null AR cistrome is enriched in the AR cistrome of PCa tumors
 - Induction of HOXB13 alone is sufficient to phenocopy the CHD1 null AR cistrome
 - CHD1 loss impacts the AR cistrome upstream of cofactor recruitment
 - CHD1 loss impairs chromatin remodeling of a subset of ARE-containing enhancers, and allows maintained accessibility to AR repressed HOXB13 sites.
- CHD1 null tumors display a unique expression pattern of AR score genes
 - The AR score alone is insufficient to accurately assess AR activity across subclasses
 - Loss of CHD1 results in a large and divergent AR transcriptome
 - The CHD1 null AR signature is concordant with signaling profiles from CHD1 null tumors only
 - This signature is enriched for pro-oncogenic pathways & depleted for normal AR-driven prostate functions
- CHD1 null prostate cancer cells respond similarly to AR directed therapeutics
 - Unbiased drug screens identified taxanes and a unique PARP inhibitor as potential therapeutic options for patients whose tumors are CHD1 deficient.


Prelim Data

Aim 1

Aim 2

Aim 3

Graphical abstract -Years 1-2 conclusions



Professional Development:

Invited Lectures:

- 2017 10th Annual Multi-Institutional Prostate Cancer Program SPORE Retreat: **“Defining the impact of CHD1 deregulation on the AR cistrome and PCa progression”** Fort Lauderdale FL
- 2018 Prostate Cancer Foundation - Genomics/ Genetics/ Epigenetics Webinar Series **“Uncoupling the tumor suppressive and oncogenic functions of CHD1 during prostate tumorigenesis”**
- 2019 EIPM International Cancer Precision Medicine Workshop **“CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis”** New York, NY June 27-28.

Scientific Presentations:

- 2017 Prostate Cancer Foundation Retreat **“Consequence of CHD1 loss on cistrome dynamics and prostate cancer progression”** Washington DC, 2017.
- 2017 AACR Special Conference on Advances in Prostate Cancer Research: **“Consequence of CHD1 loss on cistrome dynamics and prostate cancer progression”** Orlando Florida, December 2-5, 2017
- 2018 11th Annual Multi-Institutional Prostate Cancer Program SPORE **“Defining the impact of CHD1 loss on AR driven oncogenic programming”** Ft. Lauderdale FL. March 4-6, 2018
- 2018 Prostate Cancer Foundation Retreat **“CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis”** Carlsbad CA, October 22-26.
- 2019 12th Annual Multi-Institutional Prostate Cancer Program SPORE **“CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis”** Ft. Lauderdale FL. March 4-6, 2019

Dissemination of Results: Nothing to report

4: Impact

Impact on Principle Discipline: Prostate cancer (PCa) is a highly heterogeneous and lethal disease responsible for a majority of cancer-related deaths in men within the US. Currently, unlike other cancer types, there is a lack of molecular targets available that can help direct therapeutic intervention to thwart disease progression. As such, there is a critical need for the identification and development of novel therapeutic targets to limit cancer growth. Work from our group and others have characterized the genomic landscape of primary PCa and uncovered novel subtypes of this disease, each encompassing unique chromosomal aberrations, mutations, and transcriptional

signatures associated with disease initiation. One of the most common subtypes is characterized by the homozygous loss of the chromatin remodeler CHD1, representing up to 20% of all primary prostate tumors. Interestingly, CHD1 deficiency is highly specific to prostatic tumors, suggesting that this lesion could represent a window for therapeutic intervention. These findings support my objective of defining the consequence of CHD1 loss on transcriptional programs known to drive PCa progression, and nominate molecular pathways that can be targeted to specifically thwart progression of this aggressive subtype. With the completion of this proposal, FDA approved options have been nominated to specifically limit progression of this specific subtype.

Impact on other Disciplines: Nothing to report

Impact on Technology Transfer: Nothing to report

Impact Beyond Science and Technology: Nothing to report

5: Changes/Challenges

Changes in approach: Nothing to report

Actual or anticipated problems:

All components of the original proposal have been completed.

Changes in expenditure, use of animals, or biohazards: Nothing to report

Products: Augello et. al, “CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis” Published in Cancer Cell April 15, 2019; 35(4):603-617.e8

Participants and other Collaborating Organizations:

Name:	Michael Augello
Project Role:	PI
Nearest person months worked	24
Contribution to Project	Designed, performed, and analyzed all experiments for this project
Funding Support:	Department of Defense Post-Doctoral Fellowship Award PC160994


Changes in personnel: Nothing to report

Other Organization Involved: Nothing to report

Cancer Cell

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

Graphical Abstract



Authors

Michael A. Augello, Deli Liu, Lesa D. Deonarine, ..., Andrea Sboner, Noah Dephoure, Christopher E. Barbieri

Correspondence

chb9074@med.cornell.edu

In Brief

Augello et al. show that CHD1 binds prostate-specific enhancers enriched for the androgen receptor (AR). Upon CHD1 loss, which occurs often in prostate cancer (PCa), the AR cistrome changes to be consistent with that in PCa and is associated with an AR transcriptional signature unique to this subclass of PCa.

Highlights

- CHD1 acts as a prostate-specific tumor suppressor *in vivo*
- CHD1 regulates AR occupancy at a subset of lineage-specific enhancers
- Loss of *CHD1* redistributes the AR cistrome to favor oncogenic AR-driven pathways



CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

Michael A. Augello,^{1,2} Deli Liu,^{1,2,3} Lesa D. Deonarine,^{1,2} Brian D. Robinson,^{4,5} Dennis Huang,^{1,2} Suzan Stelloo,⁶ Mirjam Blattner,^{1,4} Ashley S. Doane,³ Elissa W.P. Wong,⁷ Yu Chen,^{7,8} Mark A. Rubin,^{2,4,5} Himisha Beltran,^{2,5,9} Olivier Elemento,^{3,4,5} Andries M. Bergman,^{6,10} Wilbert Zwart,^{6,11} Andrea Sboner,^{2,3,4,5} Noah Dephoure,^{2,12} and Christopher E. Barbieri^{1,2,5,13,*}

¹Department of Urology, Weill Cornell Medicine, New York, NY 10065, USA

²Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA

³The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA

⁴Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA

⁵Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10065, USA

⁶Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands

⁷Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁸Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁹Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA

¹⁰Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

¹¹Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands

¹²Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA

¹³Lead Contact

*Correspondence: chb9074@med.cornell.edu

<https://doi.org/10.1016/j.ccell.2019.03.001>

SUMMARY

Deletion of the gene encoding the chromatin remodeler CHD1 is among the most common alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and reasons for its tissue-specific loss remain undefined. We demonstrated that CHD1 occupied prostate-specific enhancers enriched for the androgen receptor (AR) and lineage-specific cofactors. Upon *CHD1* loss, the AR cistrome was redistributed in patterns consistent with the oncogenic AR cistrome in PCa samples and drove tumor formation in the murine prostate. Notably, this cistrome shift was associated with a unique AR transcriptional signature enriched for pro-oncogenic pathways unique to this tumor subclass. Collectively, these data credential CHD1 as a tumor suppressor in the prostate that constrains AR binding/function to limit tumor progression.

INTRODUCTION

Precise regulation of chromatin signaling is essential for virtually all cellular processes, and chromatin dysregulation has recently emerged as a hallmark of cancer (Kadoch et al., 2013; Shen and

Laird, 2013). In prostate cancer (PCa), alterations in epigenetic modifiers and chromatin remodelers are prevalent across the spectrum of the disease (Barbieri et al., 2012; Cancer Genome Atlas Research Network, 2015; Grasso et al., 2012; Kumar et al., 2011; Taylor et al., 2010). The most common of these is

Significance

Deletion of the *CHD1* locus occurs in approximately 15% of primary prostate cancer (PCa) cases, and is uniquely restricted to tumors of this tissue type. Our data uncover an enrichment of CHD1 at lineage-specific enhancers, which is required to constrain oncogenic androgen receptor (AR) binding and limit prostate neoplasia *in vivo*. The discovery that CHD1 can regulate nuclear receptor activity on chromatin not only reveals a promoter-independent role for this nucleosome remodeler, but also credentials CHD1 as a bona fide tumor suppressor within prostate tissue. These findings provide needed insight into the underlying mechanisms and pathways of subclass-specific PCa development, and, more broadly, highlight the importance of deregulation of chromatin architecture in the development and progression of human cancer.



recurrent deletion of *CHD1*, encoding chromodomain helicase DNA-binding protein 1 (CHD1), which occurs in approximately 15% of primary human PCa (Barbieri et al., 2012; Barbieri and Tomlins, 2014; Cancer Genome Atlas Research Network, 2015; Kumar et al., 2011; Liu et al., 2012; Wedge et al., 2018). In normal tissue, CHD1 is ubiquitously expressed and functions as an ATP-dependent chromatin remodeler, localizing to promoters of actively transcribed genes marked by trimethylation of histone H3K4 (H3K4me3), and initiates nucleosome turnover to facilitate transcriptional initiation (de Dieuleveult et al., 2016; Flanagan et al., 2005; Lusser et al., 2005; Morettini et al., 2011; Siggins et al., 2015; Simic et al., 2003; Skene et al., 2014). Phenotypically, germline disruption of *Chd1* in mice is embryonically lethal, and it is required for maximally efficient transcription, cellular differentiation, and growth (Baumgart et al., 2017; Gaspar-Maia et al., 2009; Guzman-Ayala et al., 2015; Koh et al., 2015; Piatti et al., 2015). However, how disruption of these functions contributes to neoplastic formation within the prostate remains undefined.

RESULTS

Chd1 Limits Prostate Tumorigenesis *In Vivo*

Previous reports have demonstrated that homozygous deletion of *CHD1* is frequently observed in PCa (Barbieri et al., 2012; Barbieri and Tomlins, 2014; Cancer Genome Atlas Research Network, 2015; Taylor et al., 2010), which we validated in our patient cohort (Figure 1A). Importantly, loss of *CHD1* was largely restricted to tumors of prostate lineage (Figure 1A), rarely deleted in other cancer types (Cancer Genome Atlas Research Network, 2015), suggesting prostate-specific tumor-suppressive functions for CHD1. We therefore crossed mice carrying a *Chd1*-floxed allele (*Chd1^{fl/fl}*) with *Pb-Cre4* mice (Wu et al., 2001) to specifically delete *Chd1* in prostate epithelial cells to define the impact of its loss on prostate pathobiology (Figure 1B). At 1 year, there were no observed differences in histopathology, androgen receptor (AR) expression, or glandular structure due to *Chd1* homozygous loss (Figures 1C and S1A). This is consistent with previous reports of CHD1 function in prostate tissue (Shenoy et al., 2017), and suggest that, like other well-established drivers of PCa in human disease, such as ERG (Chen et al., 2013) and ETV1 (Baena et al., 2013), deregulation of *Chd1* alone is insufficient to drive tumorigenesis in the mouse prostate.

Given the importance of androgen signaling in this tissue, we next characterized the impact of *Chd1* loss on androgen-driven regrowth of prostate tissue after castration. Mice were castrated 2 weeks before subcutaneous implantation of testosterone pellets. Following an additional 2 weeks for prostatic regrowth, tissues were assessed for pathological phenotypes (Figures 1D, S1B, and S1C). Both *Chd1^{+/+}* and *Pb-Cre;Chd1^{fl/fl}* mice responded similarly to castration, exhibiting prostate regression, diminished gland size, and cytoplasmic staining of AR (Figure S1B). In response to androgen re-stimulation, both genotypes were capable of regenerating luminal structures with strong nuclear AR staining (Figure S1B); however, *Chd1*-deficient mice showed increased proliferation (Ki67 staining) in regenerated epithelium (Figures 1D and S1C). These data demonstrate that deletion of *Chd1* in prostatic tissue may lead to neoplastic phenotypes that are androgen dependent.

PTEN is a well-characterized tumor suppressor in PCa, and acceleration of neoplastic phenotypes in *Pten*-deleted mouse prostates have been considered key “base models” to examine the tumor-suppressive functions of other genomic alterations (Grabowska et al., 2014). To define the impact of *Chd1* loss in promoting/accelerating pathological phenotypes we crossed *Chd1^{fl/fl}* mice with mice in a conditional *Pten*-deleted background. At 1 year, while heterozygous loss of *Pten* alone has a minimal phenotype in the murine prostate (Trotman et al., 2003; Wang et al., 2003), *Pb-Cre4;Chd1^{fl/fl};Pten^{f/+}* demonstrated a high penetrance of focal high-grade prostatic intraepithelial neoplasia (HG-PIN) (Figures 1E and 1F), with high levels of AR and elevated proliferative indices (Figures S1D and S1E). Furthermore, while homozygous loss of *Pten* alone in the murine prostate resulted in diffuse HG-PIN (Trotman et al., 2003), prostate lesions in *Pb-Cre4;Chd1^{fl/fl};Pten^{fl/fl}* frequently progressed to invasive carcinoma by 1 year of age (Figures 1E–1G). Histologically, these prostates were generally poorly differentiated, showed elevated proliferative indices, and remained AR positive (Figures 1E, S1E, and S1F). Together, these results demonstrate that *Chd1* loss cooperates with established drivers of PCa to promote tumor development *in vivo*, and provide evidence to credential *Chd1* as a bona fide tumor suppressor in prostate tissue.

CHD1 Localizes to the Promoters of Actively Transcribed Genes in PCa Models

To uncover the mechanisms responsible for the tumor-suppressive functions of CHD1, the cistrome of CHD1 and transcriptionally active (H3K4me3) and repressive (H3K27me3) histone marks were defined in AR-positive PCa cells (Figures 2A, S2A, and S2B). Consistent with its known function, CHD1 peaks frequently overlapped with H3K4me3, and were largely independent of the repressive H3K27me3 cistrome (Figures 2A and 2B). These binding patterns were consistent across ~21,000 RefSeq genes, in which CHD1 co-localized near the promoters of actively transcribed genes marked by H3K4me3, independent of H3K27me3 (Figures 2C–2E). CHD1 binding was enriched (along with H3K4me3) near the +1 nucleosome position (Figure 2D), and positively correlated with elevated transcript abundance (Figure 2F). These findings suggest that the canonical, promoter-specific role of CHD1 is conserved in prostate models, and indicate that the mechanisms underlying the tumor-suppressive action of CHD1 are likely independent of these functions.

The CHD1 Interactome Is Enriched for Nuclear Receptor Cofactors

To further characterize the function of CHD1 in prostate tissue, the chromatin-bound interactome of CHD1 was defined using rapid immunoprecipitation and mass spectrometry of endogenous peptides (RIME) (Mohammed et al., 2016; Stelloo et al., 2018a), with the interactome of H4K4me3 used as a promoter-specific control. Consistent with the overlap in their cistromes, 97 out of 293 (~33%) of the CHD1 interactome was shared with that of H3K4me3 and was enriched for proteins known to localize to promoters (e.g., POLR2A and POLR2B) (Tables S1 and S2). Importantly, a large portion of the CHD1 interactome was unique to CHD1, and was enriched for transcriptional regulators reported




Figure 1. Genomic Loss of *Chd1* Drives Progression of Prostate Carcinoma In Vivo

(A) *CHD1* homozygous deletions in the TCGA database (Cancer Genome Atlas Research Network, 2015) (histogram) and Weill Cornell Institute for Precision Medicine database (Pauli et al., 2017; C.P., unpublished data).

(B) Schematic of inducible *Chd1* knockout in the murine prostate.

(C) H&E staining of prostates from *Chd1*^{+/+} and *Chd1*^{ff} mice in a *Pb-Cre* background at 1 year. Scale bar, 50 μ m.

(D) Schematic of castration-testosterone re-supplementation in *Chd1*^{+/+} (n = 4) and *Chd1*^{ff} (n = 6) mice (top), and quantification of Ki67 staining after testosterone (T-pellet) re-supplementation (bottom). Scale bar, 50 μ m. Data represent \pm SEM.

(E) H&E staining of murine prostates at 1 year. Scale bar, 50 μ m.

(F) Quantification of pathological features per genotype at 1 year.

(G) Prostatic mass from 1-year-old mice (sum of all lobes). Boxes represent the mean and interquartile range, with min and max values indicated.

See also Figure S1.




Figure 2. ChD1 Colocalizes to the Promoters of Actively Transcribed Genes in PCa Models

(A) Overlap of ChD1, H3K4me3, and H3K27me3 ChIP-seq peaks from LNCaP cells under androgen-proficient conditions.

(B) Representative binding of each factor on chromatin.

(C) Heatmap of binding patterns for each factor from the transcriptional start site (TSS) to the transcriptional end site (TES) of ~21,000 RefSeq genes (gene body scaled to 3 kb, 500 bp before/after TSS/TES).

(D) Average signal of H3K4me3 and ChD1 centered at the TSS of co-bound genes (normalized by reads per kilobase of transcript per million mapped reads [RPKM]).

(E) Signal of ChD1 at all H3K4me3 or H3K27me3 peaks.

(F) Ranked normalized RNA-seq transcripts obtained from androgen-proficient conditions (GEO: GSE43785; Chen et al., 2015) ordered from most abundant (top) to least abundant (bottom), and the signal of ChD1, H3K4me3, and H3K27me3 are plotted for each gene, centered around the TSS. Two-tailed spearman correlations are reported for each comparison; $p < 0.0001$ for all correlations.

See also Figure S2.

to affect nuclear receptor function (Figure 3A; Tables S1 and S2) (Gottlieb et al., 2012; Mooslehner et al., 2012; Stelloo et al., 2018a). While the ChD1 interactome did not contain nuclear receptors directly, the RIME-derived interactome of AR significantly overlapped with that of ChD1 (Figures 3A and 3B), sharing 45%

(33/73) of its chromatin-bound cofactors with ChD1 (Figure 3B). Consistent with this observation, proximity ligation assays confirmed that ChD1 and AR associate in nuclear foci on chromatin in an androgen-dependent manner (Figure 3C). These observations define the promoter-independent interactome of




Figure 3. The CHD1 Interactome Is Enriched for AR Cofactors

(A) RIME was performed for H3K4me3 and CHD1 in androgen-proficient conditions. Signal-to-noise ratios of significantly enriched peptides from H3K4me3 were subtracted from those of CHD1 and plotted by biological replicate. Orange: peptides unique to H3K4me3; blue, unique to CHD1; purple, common; green, overlap with reported AR interactors (Gottlieb et al., 2012; Mooslehner et al., 2012).

(B) STRING analysis of AR (Stelloo et al., 2018a) and CHD1 interactomes in LNCaP cells.

(C) Proximity ligation assay (PLA) for AR and CHD1 in LNCaP cells (left), and quantification of PLA signal from a single plane, plotted as the number of detected foci per cell (right). One-way ANOVA, Tukey's multiple comparisons test: ** $p < 0.01$, **** $p < 0.00001$. Data represent \pm SEM. Scale bar, 20 μ m.

See also Tables S1 and S2.

CHD1 and implicate CHD1 as a potential regulator of lineage-specific nuclear receptor activity.

CHD1 Colocalizes to Enhancers Enriched for AR and Its Cofactors

Nuclear receptors (including AR) bind enhancers across the genome at intronic and intergenic sites, largely independent of promoters (Kininis and Kraus, 2008). While the canonical functions of CHD1 have been described at promoters, its interactome further suggests a role in regulating nuclear receptor activity at enhancers. To define promoter-independent roles of CHD1, we annotated the CHD1 and H3K4me3 cistromes in prostate models. Approximately 20% of all CHD1 peaks were shared with H3K4me3, which localized at or near the promoters of actively transcribed genes (Figure 4A). Notably, ~80% of the CHD1 cistrome was found to be independent of direct

H3K4me3 binding; these regions were heavily enriched for intronic/intergenic DNA and lacked promoter-specific regions (Figure 4A). Although no specific motifs were highly enriched across all CHD1 peaks (Figure S3), an unbiased motif analysis of CHD1 promoter-independent peaks revealed enrichment of motifs implicated in AR signaling (e.g., androgen response element [ARE], FOXA1, and HOXB13) (Figure 4B). Furthermore, these enhancer-specific binding events were highly concordant with those of the AR cistrome, as ~40% of all high-confidence AR peaks overlapped with that of CHD1, independent of H3K4me3 (Figure 4C). Strikingly, similar patterns of peak overlap were also seen between CHD1 and several established regulators of AR function, including FOXA1 (Zhao et al., 2016), HOXB13 (Pomerantz et al., 2015), and ETV1 (Chen et al., 2013) (Figure 4D-Top). Previous work characterizing the landscape flanking chromatin-bound AR described a bimodal distribution




Figure 4. CHD1 Colocalizes to Enhancers Enriched for AR and Its Cofactors

(A) Overlap of CHD1 and H3K4me3 ChIP-seq peaks in LNCaP cells under androgen-proficient conditions (top) and annotation of the common and unique peaks for H3K4me3 and CHD1 plotted as a percentage of all peaks (bottom).

(B) Motif analysis of CHD1 peaks binned into promoter/TSS or intronic/intergenic categories (200-bp window).

(C) Overlap of CHD1, AR, and H3K4me3 ChIP-seq peaks (top), and snapshot of AR, CHD1, and H3K4me3 signal at the *KLK3* locus (bottom).

(D) Overlap between CHD1 and AR, HOXB13 (GEO: GSE70079; Pomerantz et al., 2015), ETV1 (GEO: GEO47120; Chen et al., 2013), or FOXA1 (GEO: GSE69043; Zhao et al., 2016) ChIP-seq peaks in LNCaP cells under androgen-proficient conditions (top) and normalized average signal profile of CHD1 and each transcription factor at the peak center (bottom).

See also Figure S3.

of nucleosome density defined by the active enhancer mark H3K4me2, which undergoes active chromatin remodeling upon AR activation (He et al., 2010). As CHD1 has been shown to colocalize with H3K4me2 (Flanagan et al., 2005; Sims et al., 2005), we next analyzed the profile of CHD1 around AR and cofactors for evidence of nucleosome remodeling. Within a 2-kb window, the binding profile of CHD1 density around AR, FOXA1, HOXB13, and ETV1 was consistent with the bimodal nucleosome distribution exhibited by AR-bound, enhancer-associated chromatin (Figure 4D, bottom). Together, these data define an enhancer-specific role for CHD1 in the prostate and nominate CHD1 as a context-dependent chromatin remodeler for a subset of AR binding sites.

CHD1 Loss Redistributes the AR Cistrome to HOXB13-Enriched Sites

In normal prostate epithelial tissue, AR serves to limit cell growth and promote luminal differentiation (Litvinov et al., 2003). During cancer pathogenesis, the AR cistrome is expanded and driven toward sites that govern oncogenic programs (Pomerantz et al., 2015). However, the underlying mechanisms responsible for such reprogramming remain incompletely understood. Given the role of CHD1 at AR-associated enhancers, we hypothesized that *CHD1* loss would alter AR signaling in prostate cells. Accordingly, we deleted *CHD1* via CRISPR in the LNCaP line (sgCHD1) and validated complete loss of CHD1 protein (Figures 5A and S4A). In contrast to other cell types (Guzman-Ayala et al.,




Figure 5. AR Binding Is Redistributed in the Absence of *CHD1*

(A) Immunoblot (top) and immunofluorescence (bottom) of LNCaP CRISPR-Cas9 cell lines with Ctrl or *CHD1*-specific sgRNA. Scale bar, 20 μ m. (B) Growth curve of sgCtrl (left) and sgCHD1 cells (right) in response to increasing doses of dihydrotestosterone (DHT). Data represent \pm SEM. (C) ChIP-seq of differential AR binding between sgCtrl and sgCHD1. (D) RPKM-normalized AR signal (sgCtrl signal subtracted from sgCHD1 signal) at sites enriched or depleted with *CHD1* loss (left) and snapshots of sgCHD1-enriched and -depleted AR peaks (right). (E) AR ChIP-seq from (GEO: GSE70079; Pomerantz et al., 2015) patient tumors centered at sgCHD1 enriched and -depleted sites. (F) H3K27ac ChIP-seq from annotated primary PCa tumors (GEO: GSE96652; Kron et al., 2017) binned into *CHD1* null and *CHD1* WT categories. Average signal is plotted at sgCHD1-enriched and -depleted AR sites. See also Figures S4 and S5.

2015; Koh et al., 2015; Piatti et al., 2015), deletion of *CHD1* did not impair cell growth or tumorigenicity in a prostate-specific background (Figures S4B–S4G). Importantly, these cells remained highly AR-positive and sensitive to androgen withdrawal and AR antagonists (Figures 5A, S4B, and S4C), demonstrating that they accurately recapitulate critical features of primary disease. Furthermore, while low dose androgen was sufficient to engage the cell cycle in both parental and sgCHD1 cells, sgCHD1 cells were resistant to the growth-inhibitory effects of high-dose androgen (greater than 1 nM) (Figures 5B and S4H). It has been postulated that this growth-suppressive phenotype (Gao et al., 2016; Roediger et al., 2014) is due to a potential restoration of a “normal-like” AR transcriptional program (Gao et al., 2016). This suggests that *CHD1*-deficient prostate cells are compromised in their ability to engage this growth-suppressive AR cistrome, consistent with the proliferative phenotype seen in *Chd1* null regenerating prostates (Figures 1D and S1A–S1C).

Next, we directly assessed the impact of *CHD1* loss on genome-wide localization of AR in sgCHD1 models. While loss of *CHD1* did not impair the ability of AR to associate with chro-

matin globally, we detected roughly 21,400 AR peaks that were differentially bound in the absence of *CHD1* (Figures 5C and S5A–S5C). These peaks were approximately equally distributed between enhanced (11,193) and diminished (10,278) AR binding, with nearly identical distribution across all genomic annotation classes except promoters, in which enriched peaks were less abundant (1.6% versus 5.3%) (Figures 5C, 5D, and S5D). To determine the relevance of this *CHD1* null AR cistrome to human tumors, we examined AR occupancy at these sites in primary human PCa ($n = 13$) and normal prostate ($n = 7$) samples (Pomerantz et al., 2015). The tumor-associated AR cistrome mirrored that of the *CHD1* null model, demonstrating elevated AR signal at enriched compared with depleted sites (Figure 5E). This distinction was unique to the tumor cistrome of AR; the signal was universally weaker and no differences were observed between enriched or depleted sites in normal prostate tissue (Figure S5E). Similarly, epigenetic marks of active enhancers, H3K27ac (Kron et al., 2017), were elevated at AR-enriched sites in *CHD1* null tumors compared with wild-type (WT) tumors, further supporting the relevance and subclass specificity of these sites (Figures 5F,




Figure 6. AR Is Enriched at HOXB13 Sites in CHD1 Null Tumors

(A) Heatmap of differential motif enrichment between sgCHD1-enriched and -depleted AR sites (left) and histogram of the average incidence of the HOXB13 (top) and AR half-site (bottom) motifs from the peak center (right).

(B) ChIP-seq for HOXB13 derived from LNCaP and primary human PCa (GEO: GSE70079; Pomerantz et al., 2015) was plotted at sgCHD1-enriched and -depleted AR sites.

(C) Average ChIP-seq signal for AR in control (left) and HOXB13-expressing (right) LACSAR cells at sgCHD1-enriched and -depleted AR sites (GEO: GSE70079; Pomerantz et al., 2015).

(D) AR ChIP-seq peaks from primary human prostate tumors (GEO: GSE120742; Stelloo et al., 2018b) binned into CHD1-deficient and CHD1 WT categories, merged, and assessed for overlap.

(E) De novo motif analysis for CHD1-deficient tumor peaks (compared to CHD1 WT tumors) and enriched (blue) and de-enriched (red) motifs plotted according to rank and p value. Values next to motifs represent the best match motif score (out of 1). Gray indicates motifs with less significant p values.

(legend continued on next page)

S5F, and S5G). Thus, these data implicate CHD1 as a regulator of nuclear receptor occupancy on chromatin and identify a clinically relevant AR cistrome in *CHD1*-deficient prostate cells.

To more completely define the mechanistic basis of AR rewiring by *CHD1* deletion, we analyzed the *CHD1* null AR cistrome for motif enrichment. Within a 200-bp window, the HOXB13 motif was frequently observed within the enriched AR peaks, while AR half-sites (a weaker AR binding motif containing only half of the canonical ARE) were significantly depleted (Figure 6A; Table S3). This motif pattern was highly consistent with the AR cistrome of human tumors, which demonstrated a shift away from mainly canonical ARE motifs and expanded to sites enriched for oncogenic AR cofactors (e.g., HOXB13) (Pomerantz et al., 2015) (Figures S6A and S6B). Other factors known to drive alternative AR binding patterns (e.g., FOXA1) were equally present in both datasets, suggesting that HOXB13 activity may underlie the divergent AR cistrome observed upon *CHD1* loss. Indeed, HOXB13 occupancy at AR-elevated sites was enriched in both human PCa tumors and LNCaP models (Pomerantz et al., 2015) (Figure 6B), validating that the motifs identified are actively bound HOXB13 sites. To determine the sufficiency of HOXB13 deregulation in promoting *CHD1* null phenotypes, we next interrogated the AR cistrome in non-tumorigenic LHSAR prostate cells in the presence and absence of exogenous HOXB13 expression (Pomerantz et al., 2015). In control cells, AR was more frequently bound at sgCHD1-depleted sites, consistent with the maintenance of a normal AR program (Figure 6C, left). However, upon HOXB13 induction, AR was redistributed to sgCHD1-enriched sites, phenocopying AR binding in the absence of *CHD1* (Figure 6C, right). To uncover how CHD1 regulates these phenotypes, we analyzed the motif enrichment of HOXB13 peaks overlapping with, or independent of, the CHD1 cistrome. Interestingly, co-bound peaks more frequently contained canonical AREs whereas CHD1-independent HOXB13 peaks were enriched for HOX and GATA motifs (Figure S6C). These CHD1-insensitive peaks contained nearly one-third of all AR peaks enriched in *CHD1* null cells and were largely independent of the AR-depleted sites within the same model (Figure S6C). Collectively these data suggest that CHD1 localizes to chromatin-containing canonical AR binding sites, and, upon its loss, AR is redistributed to regions enriched for other cofactors (e.g., HOXB13) that are insensitive to CHD1 activity. These data implicate HOXB13 as a driver of the *CHD1* null AR cistrome.

To validate the relevance of this shift in motif preference in human PCa samples, we analyzed the AR cistromes of primary PCa samples annotated for *CHD1* genomic status (Stelloo et al., 2018b). Collectively, the number of AR binding sites was nearly equal between *CHD1*-deficient and *CHD1* WT tumors (39,745 versus 36,420), and a majority of these AR peaks were common between the two groups (Figure 6D), consistent with the AR cistromes in our isogenic LNCaP models of *CHD1* loss (Figures 5C and S5B). Importantly, however, differential motif analyses of

these collective peak sets uncovered a significant enrichment for HOXB13 and GATA, and a depletion of canonical ARE and AR half-site motifs in *CHD1*-deficient tumors (Figure 6E). This pattern is highly consistent with the motif enrichment patterns uncovered in our preclinical *CHD1* null models (Figure 6A) and provides compelling evidence to nominate CHD1 as a clinically relevant regulator of the AR cistrome.

To define how CHD1-regulated changes in chromatin accessibility relate to differential AR binding patterns across the genome, we performed ATAC sequencing (ATAC-seq) in the presence and absence of androgen in our isogenic models of *CHD1* loss. As expected, ARE motifs were largely absent from ATAC peaks under androgen-deprived conditions (Figure 6F). Upon androgen stimulation, AREs were enriched 2.7-fold in control cells, but only ~1.8-fold in the sgCHD1 line (Figure 6F), consistent with changes in the AR cistrome upon *CHD1* deletion. Parallel analyses of the HOXB13 motif showed an unexpected depletion (~25%) in control cells post-androgen stimulation (Figure 6F), with similar effects observed in chromatin immunoprecipitation sequencing (ChIP-seq) datasets derived from prostate-specific active enhancer marks (H3K27ac and H3K4me2), as well as HOXB13 itself (Figures S6D and S6E). Importantly, sgCHD1 cells showed no significant reduction of HOXB13 motifs in ATAC peaks post-androgen stimulation (Figure 6F). Collectively, the motif-enrichment patterns of *CHD1* null open chromatin peaks mirrored those observed in the AR cistrome upon *CHD1* deletion, suggesting that CHD1 is required for optimal chromatin remodeling of a subset of ARE and HOXB13 sites in response to androgen. These observations highlight a mechanism of AR rewiring in PCa and suggest that CHD1 is critical to maintain a chromatin state required for normal AR function.

Finally, to determine if HOXB13 deregulation was sufficient to phenocopy the *CHD1*-regulated growth effects in prostate cells, we overexpressed HOXB13 and assessed the impacts on androgen-driven growth. Therein, induction of HOXB13 was sufficient to phenocopy the biological effects of *CHD1* deletion, promoting resistance to high-dose androgens in a manner similar to *CHD1* loss (Figure 6G). Together, these analyses implicate HOXB13 as a major driver of the *CHD1* null AR cistrome, and suggest that CHD1 functions as a tumor suppressor by limiting binding of AR to canonical sites.

Loss of *CHD1* Drives a Unique AR Transcriptome Associated with Activation of Oncogenic Pathways

To define transcriptional programs impacted by *CHD1* deletion, we conducted gene set enrichment analysis of pathway hallmarks using RNA sequencing (RNA-seq) data derived from three independent models of *CHD1* deficiency, including human LNCaP sgCHD1 lines, Cre-inducible *Chd1^{fl/fl}* murine organoids (Figures S7A and S7B), and *CHD1* null primary PCa samples (The Cancer Genome Atlas [TCGA]) (Cancer Genome Atlas Research Network, 2015). Interestingly, the canonical Androgen

(F) ATAC-seq in the sgCHD1 isogenic model \pm 4 h of DHT. 20k peaks/condition were randomly assessed for ARE and HOXB13 motif enrichment 100 \times . Plotted are the number of ARE (top) and HOXB13 (bottom) motifs per 20k peaks (left) and histogram of mean ARE and HOXB13 motif enrichments under DHT conditions (right). Data represent \pm SEM.

(G) Immunoblot of LNCaP cells expressing HOXB13 or vector (left) and cell growth in androgen-depleted media in response to DHT (bottom). Data represent \pm SEM.

See also Figure S6 and Table S3.




Figure 7. Loss of *CHD1* Drives a Subtype-Specific AR Transcriptome Associated with Activation of Oncogenic Pathways

(A) 3D representation of gene set enrichment analysis (GSEA) hallmark enrichment for three independent datasets deficient in *CHD1*. Normalized enrichment scores (NES) for all hallmarks for each *CHD1* null model (versus WT counterpart) are plotted on the x (LNCaP), y (murine organoid), and z (*CHD1* null human tumors) axes. Hallmarks with consistent de-enrichment (blue) or enrichment (red) are highlighted (boxes). Gray dots represent inconsistent enrichment patterns. Individual NESs for each highlighted hallmark and dataset are shown.

(B) TCGA RNA-seq data were annotated for the status of *ERG*, *ETS*, and *CHD1*, and AR score plotted for each tumor. The box shows interquartile range with median (solid line) and min and max (whiskers) indicated.

(C) Z scores of all genes in the AR score were averaged per subclass and plotted by rank. Highlighted: the three top (red) and bottom (blue) genes contributing to the *CHD1* null AR score.

(D) RNA-seq from sgCtrl and sgCHD1 cells stimulated with androgen for 0, 3, or 8 h. Normalized Z scores of AR score genes for each model. Diminished and elevated genes have a p value of < 0.05 and fold change cutoff of 1.3x.

(E) Ranked normalized Z scores of AR score genes from the sgCHD1 model. Average Z scores from TCGA tumor subclasses and sgCtrl were used to cluster datasets based on the sgCHD1 ranked list.

(F) AR signature of sgCHD1 cells. Adjusted p < 0.05.

(legend continued on next page)

Response was the most significantly de-enriched pathway among all three datasets (Figure 7A). This result is consistent with the proposed role of *CHD1* loss in deregulating conventional AR signaling networks, and demonstrates that the chromatin context of nuclear receptor signaling is a critical factor in defining downstream transcriptional programs.

An additional metric to assess global AR function is via the AR score (Hieronymus et al., 2006), a well-established 20-gene panel that, unlike the AR Response signature, is used to assess the level of AR transcriptional activation rather than downstream biological pathways. Thus, we next used the AR score to assess the level of AR activation in *CHD1*-deficient human tumors to determine if the de-enrichment of the hallmark Androgen Response in *CHD1* null models could be attributed to diminished AR activity. Contrary to the AR signature, AR activity by this metric was significantly higher in *CHD1* null tumors as compared with subtypes driven by ERG or ETS factors (Figure 7B). Collectively, these results suggest that AR activity is not simply impaired in *CHD1*-deficient tumors, but rather that this subtype engages a unique, AR-dependent transcriptome.

To begin defining the specific AR transcriptome in *CHD1* null tumors, we analyzed the expression patterns of the genes comprising the AR score across subclasses of PCa. Consistent with the findings above, we uncovered unique patterns of expression among subclasses (Figure 7C). While ERG and ETS AR signatures were relatively concordant, an inverted expression pattern was detected when compared with *CHD1* null tumors, further implicating *CHD1* loss in driving alternative AR programs (Figure 7C). To directly assess the impact of *CHD1* loss on AR-driven transcription, we stimulated sgCtrl and sgCHD1 models with dihydrotestosterone (DHT) and examined gene expression at 3 and 8 h. Therein, deletion of *CHD1* led to the diminished induction and increased expression of 35% and 10% of AR score genes, respectively (Figure 7D). Hierarchical clustering of cell line and tumor samples based on ranked AR scores showed that the sgCHD1 signature mirrored that of *CHD1* null tumors and was sufficient to segregate *CHD1*-deficient samples from *CHD1* proficient samples (Figure 7E). Similar results were also achieved by using a TCGA-derived signature of *CHD1* loss (Figure S7C). These findings describe subtype-specific AR transcriptional regulation in PCa and further nominate *CHD1* loss as a critical regulator of subtype-specific AR programs.

While the established AR score is a broadly effective metric to estimate AR activity, the finding of distinct, subtype-specific AR transcriptional programs suggests context-dependent regulation of downstream pathways. Therefore, we generated a gene expression signature specific to sgCHD1 cells after AR stimulation with DHT. Compared with control cells, 514 genes were downregulated and 605 were upregulated in *CHD1* null cells upon androgen stimulation (Figure 7F; Table S4). AR binding peaks attributed to transcriptional induction of genes in sgCHD1 cells were also enriched for HOXB13 and GATA motifs, consistent with *CHD1*-dependent changes in the AR cistrome (Fig-

ure S7D). We next tested the subtype specificity of this AR signature in human PCa tumors. Strikingly, this ranked-gene signature was highly concordant only in *CHD1*-deficient tumors and was inconsistent or discordant in other PCa subclasses (Figure 7G). An analysis of molecular pathways controlled by this AR program revealed an enrichment of oncogenic pathways relevant to PCa, and a de-enrichment of molecular processes associated with canonical prostate function (Figure 7H). Notably, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway “Prostate Cancer” was both enriched and de-enriched in the *CHD1* null AR signature, further highlighting the importance of chromatin context in defining cancer-associated networks. Combined, we conclude that *CHD1* loss drives expression of a subtype-specific AR transcriptome, with activation of oncogenic pathways and diversion away from normal prostatic functions.

DISCUSSION

The *CHD1* gene resides at one of the most commonly deleted loci in primary PCa and is uniquely restricted to this tumor type. Our data provide evidence that *CHD1* deficiency can drive tumorigenesis *in vivo*, helping to credential *CHD1* as a bona fide tumor suppressor. Mechanistically, a promoter-independent function for *CHD1* was defined at prostate-specific enhancers, where *CHD1* complexed with a number of nuclear receptor-associated cofactors and was coenriched on chromatin with AR. Loss of *CHD1* resulted in a redistribution of AR to sites enriched for HOXB13, which was associated with subtype-specific changes to the AR transcriptome. This AR signature was observed only in *CHD1* null PCa samples, and is consistent with engagement of pro-oncogenic pathways. These data provide critical insight into the context-dependent tumor-suppressive functions of *CHD1* and, more broadly, implicate deficiencies in chromatin remodeling as drivers of prostate pathogenesis.

Reprogramming of the AR cistrome is a hallmark of PCa; however, the underlying mechanisms driving such events have yet to be fully elucidated. Recent work has demonstrated that FOXA1 and HOXB13 motifs are the most tightly associated with the oncogenic AR cistrome, and deregulation of these two pioneer factors is sufficient to reprogram AR in normal cells (Pomerantz et al., 2015). Consistent with these observations, we found that *CHD1* was required to remodel local chromatin for a subset of AREs, potentially varying the available pool of unbound AR and therefore altering conventional signaling patterns of this nuclear receptor. Consequently, with *CHD1* loss we found that AR more frequently localized to accessible DNA enriched for HOXB13, which did not require *CHD1* for accessibility. This colocalization on DNA was associated with a maintenance of open chromatin at androgen-repressed HOXB13 sites, which has previously been suggested to play a pivotal role in AR reprogramming during tumorigenesis (Pomerantz et al., 2015). As such, deregulation of HOXB13 signaling underlies the redistribution of the

(G) NESs for each subclass were generated for the upregulated (orange up arrows) and downregulated (purple down arrows) genes of the sgCHD1 AR signature. The downregulated NES was subtracted from the upregulated NES for each genotype.

(H) Metascape analysis of the sgCHD1 AR signature. Red, relevant to PCa; blue, consistent with normal prostate function; purple, common. See also Figure S7 and Table S4.

AR cistrome in the absence of CHD1, providing mechanistic insight into the prostate-specific tumor suppressor functions of this chromatin remodeler.

Disruption of the HOXB13 pathway can be mediated through a variety of mechanisms and has emerged as a key event during prostate pathogenesis (Pomerantz et al., 2015). Interestingly, these alterations are frequently observed in the context of CHD1 deficiency, suggesting that disruption of these pathways converge to drive oncogenic transcriptional networks. For example, *CHD1* deletion frequently co-occurs with *SPOP* mutations in PCa (Barbieri et al., 2012; Barbieri and Tomlins, 2014; Cancer Genome Atlas Research Network, 2015), which are reported to stabilize a number of key AR cofactors, including HOXB13 (Blattner et al., 2017; Dai et al., 2017; Geng et al., 2013; Groner et al., 2016). In addition, germline *HOXB13* variants (G84E) have been associated with an increased risk for PCa development (Ewing et al., 2012), and are largely independent of ETS fusions events (similar to *CHD1* loss) (Lotan et al., 2017). Together, these events may combine to affect the context of AR-driven transcription to drive PCa progression.

These findings offer insight into subclass-specific events that drive alternative AR programs critical to prostate pathogenesis. More broadly, this work credentials chromatin remodeling deficiencies as key events in the deregulation of lineage-specific programming and highlights the importance of chromatin architecture in oncogenic transcriptional regulation. Beyond PCa, these findings suggest that tissue-specific deficiencies in other chromatin remodelers may play similar roles in transcription factor reprogramming and offer alternative therapeutic opportunities to therapeutically target these tumors.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Mouse Breeding, Genotyping, and Tissue Processing
 - Murine Organoid Generation and Growth
 - Murine Pathology Review
 - Human Cell Lines
 - CRISPR Model Generation
 - Transient Models
- **METHOD DETAILS**
 - Murine Castration-Testosterone Re-Supplementation
 - Immunofluorescence
 - Growth Assays
 - ChIP and ChIP Sequencing
 - Quantitative PCR
 - Immunoblot
 - Chromatin Tethering
 - Xenograft Studies
 - Growth Curves
 - Proximity Ligation Assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - ChIP Sequencing Analysis
 - Peak Calling

- Motif Analysis
- Motif Analysis of Primary Human Prostate Tumors
- Genomic Region Annotation
- ATAC Seq
- RNA-seq Analysis
- Generation of *CHD1* Null Transcriptional Signature from TCGA
- RIME Analysis
- Ki67 Quantification
- Tumor-Xenograft Volume Quantification
- Xenograft-Tumor Take Quantification
- PLA Quantification
- Growth Curves
- String Analyses

● DATA AND SOFTWARE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.ccell.2019.03.001>.

ACKNOWLEDGMENTS

We are grateful to the prostate cancer patients and families who contributed to this research. We thank The Cancer Genome Atlas Research Network (TCGA) and cBioPortal. We thank the WCM Genomics and Epigenomics Core Facilities, the Biospecimen and Pathology and Computational and Biostatistics Cores of the WCM SPORE in Prostate Cancer, and the Center for Functional Cancer Epigenetics at The Dana Farber Cancer Institute. Special thanks to O. Krijgsman for providing computational pipelines and to C. McNair and J. Franciosi for valuable feedback and technical assistance. This work was supported by: the NCI, United States (WCM SPORE in Prostate Cancer, P50CA211024-01 to C.E.B., K08CA187417-01, to C.E.B., R37CA215040, to C.E.B.), a Urology Care Foundation Rising Star in Urology Research Award, United States (to C.E.B.), Damon Runyon Cancer Research Foundation MetLife Foundation Family Clinical Investigator Award, United States (to C.E.B.), Department of Defense Postdoctoral Fellowship, United States (W81XWH-17-1-0137, to M.A.A.), and the Prostate Cancer Foundation, United States (to C.E.B. and M.A.A.) Prostate Cancer Foundation Young Investigator award (to M.A.A.), the Dutch Cancer Society/Alpe d'HuZes, Netherlands (10084, to W.Z.), and The Movember Foundation, Australia (NKI01, to W.Z.).

AUTHOR CONTRIBUTIONS

M.A.A. was responsible for experimental design and execution, data analysis, figure generation, and writing of the manuscript. D.L. analyzed RNA-seq data and generated signatures. L.D.D. and M.B. were responsible for murine model generation/breeding and prostate extraction. B.D.R. reviewed murine pathology. D.H. assisted in generating organoid cultures. M.A.R., H.B., O.E., and A.S. provided patient data and offered feedback and guidance. A.S.D. assisted in processing, interpretation, and analysis of ChIP-seq data. S.S., A.B., and W.Z. provided data analysis and interpretation of valuable human ChIP-seq data. N.E.D. ran and analyzed mass spectrometry data. Y.C. and E.W.P.W. provided model systems and aided in experimental design. C.E.B. coordinated and oversaw all studies.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 5, 2018

Revised: December 6, 2018

Accepted: February 28, 2019

Published: March 28, 2019; Corrected online: April 25, 2019

SUPPORTING CITATIONS

The following references appear in the Supplemental Information: Anderson et al., 2012; Hazelett et al., 2014; Magee et al., 2006; Shang et al., 2002; Wang et al., 2007.

REFERENCES

- Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* *31*, 166–169.
- Anderson, P.D., McKissic, S.A., Logan, M., Roh, M., Franco, O.E., Wang, J., Doubinskaia, I., van der Meer, R., Hayward, S.W., Eischen, C.M., et al. (2012). Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. *J. Clin. Invest.* *122*, 1907–1919.
- Augello, M.A., Burd, C.J., Birbe, R., McNair, C., Ertel, A., Magee, M.S., Frigo, D.E., Wilder-Romans, K., Shilkrut, M., Han, S., et al. (2013). Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. *J. Clin. Invest.* *123*, 493–508.
- Baena, E., Shao, Z., Linn, D.E., Glass, K., Hamblen, M.J., Fujiwara, Y., Kim, J., Nguyen, M., Zhang, X., Godinho, F.J., et al. (2013). ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. *Genes Dev.* *27*, 683–698.
- Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat. Genet.* *44*, 685–689.
- Barbieri, C.E., and Tomlins, S.A. (2014). The prostate cancer genome: perspectives and potential. *Urol. Oncol.* *32*, e15–22.
- Baumgart, S.J., Najafova, Z., Hossan, T., Xie, W., Nagarajan, S., Kari, V., Ditzel, N., Kassem, M., and Johnsen, S.A. (2017). CHD1 regulates cell fate determination by activation of differentiation-induced genes. *Nucleic Acids Res.* *45*, 7722–7735.
- Blattner, M., Liu, D., Robinson, B.D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L.D., Augello, M.A., Sailer, V., et al. (2017). SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. *Cancer Cell* *31*, 436–451.
- Buenrostro, J.D., Wu, B., Chang, H.Y., and Greenleaf, W.J. (2015). ATAC-seq: a method for assaying chromatin accessibility genome-wide. *Curr. Protoc. Mol. Biol.* *109*, 21–29.
- Cancer Genome Atlas Research Network (2015). The molecular taxonomy of primary prostate cancer. *Cell* *163*, 1011–1025.
- Chen, Y., Chi, P., Rockowitz, S., Iaquina, P.J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B.S., Wongvipat, J., et al. (2013). ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. *Nat. Med.* *19*, 1023–1029.
- Chen, Z., Lan, X., Thomas-Ahner, J.M., Wu, D., Liu, X., Ye, Z., Wang, L., Sunkel, B., Grenade, C., Chen, J., et al. (2015). Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. *EMBO J.* *34*, 502–516.
- Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong, N.A., Vesuna, S., Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., et al. (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat. Methods* *14*, 959–962.
- Dai, X., Gan, W., Li, X., Wang, S., Zhang, W., Huang, L., Liu, S., Zhong, Q., Guo, J., Zhang, J., et al. (2017). Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. *Nat. Med.* *23*, 1063–1071.
- de Dieuleveult, M., Yen, K., Hmitou, I., Depaux, A., Boussouar, F., Bou Dargham, D., Jounier, S., Humbertclaude, H., Ribierre, F., Baulard, C., et al. (2016). Genome-wide nucleosome specificity and function of chromatin remodelers in ES cells. *Nature* *530*, 113–116.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* *29*, 15–21.
- Drost, J., Karthaus, W.R., Gao, D., Driehuis, E., Sawyers, C.L., Chen, Y., and Clevers, H. (2016). Organoid culture systems for prostate epithelial and cancer tissue. *Nat. Protoc.* *11*, 347–358.
- Elias, J.E., and Gygi, S.P. (2007). Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat. Methods* *4*, 207–214.
- Ewing, C.M., Ray, A.M., Lange, E.M., Zuhlke, K.A., Robbins, C.M., Tembe, W.D., Wiley, K.E., Isaacs, S.D., Johng, D., Wang, Y., et al. (2012). Germline mutations in HOXB13 and prostate-cancer risk. *N. Engl. J. Med.* *366*, 141–149.
- Flanagan, J.F., Mi, L.Z., Chruszcz, M., Cymborowski, M., Clines, K.L., Kim, Y., Minor, W., Rastinejad, F., and Khorasanizadeh, S. (2005). Double chromodomains cooperate to recognize the methylated histone H3 tail. *Nature* *438*, 1181–1185.
- Gao, S., Gao, Y., He, H.H., Han, D., Han, W., Avery, A., Macoska, J.A., Liu, X., Chen, S., Ma, F., et al. (2016). Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein. *Cell Rep.* *17*, 966–976.
- Gaspar-Maia, A., Alajem, A., Polesso, F., Sridharan, R., Mason, M.J., Heidersbach, A., Ramalho-Santos, J., McManus, M.T., Plath, K., Meshorer, E., and Ramalho-Santos, M. (2009). Chd1 regulates open chromatin and pluripotency of embryonic stem cells. *Nature* *460*, 863–868.
- Geng, C., He, B., Xu, L., Barbieri, C.E., Eedunuri, V.K., Chew, S.A., Zimmermann, M., Bond, R., Shou, J., Li, C., et al. (2013). Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. *Proc. Natl. Acad. Sci. U S A* *110*, 6997–7002.
- Gottlieb, B., Beitel, L.K., Nadarajah, A., Paliouras, M., and Trifiro, M. (2012). The androgen receptor gene mutations database: 2012 update. *Hum. Mutat.* *33*, 887–894.
- Grabowska, M.M., DeGraff, D.J., Yu, X., Jin, R.J., Chen, Z., Borowsky, A.D., and Matusik, R.J. (2014). Mouse models of prostate cancer: picking the best model for the question. *Cancer Metastasis Rev.* *33*, 377–397.
- Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. *Nature* *487*, 239–243.
- Groner, A.C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janouskova, H., Melchers, D., Houtman, R., Cato, A.C.B., Tschopp, P., Gu, L., et al. (2016). TRIM24 is an oncogenic transcriptional activator in prostate cancer. *Cancer Cell* *29*, 846–858.
- Guzman-Ayala, M., Sachs, M., Koh, F.M., Onodera, C., Bulut-Karslioglu, A., Lin, C.J., Wong, P., Nitta, R., Song, J.S., and Ramalho-Santos, M. (2015). Chd1 is essential for the high transcriptional output and rapid growth of the mouse epiblast. *Development* *142*, 118–127.
- Habegger, L., Sboner, A., Gianoulis, T.A., Rozowsky, J., Agarwal, A., Snyder, M., and Gerstein, M. (2011). RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. *Bioinformatics* *27*, 281–283.
- Hazelett, D.J., Rhie, S.K., Gaddis, M., Yan, C., Lakeland, D.L., Coetzee, S.G., Ellipse/GAME-ON Consortium; Practical Consortium, Henderson, B.E., Noushmehr, H., et al. (2014). Comprehensive functional annotation of 77 prostate cancer risk loci. *PLoS Genet.* *10*, e1004102.
- He, H.H., Meyer, C.A., Shin, H., Bailey, S.T., Wei, G., Wang, Q., Zhang, Y., Xu, K., Ni, M., Lupien, M., et al. (2010). Nucleosome dynamics define transcriptional enhancers. *Nat. Genet.* *42*, 343–347.
- Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* *38*, 576–589.
- Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S.M., et al. (2006). Gene expression signature-based genomic prediction identifies a novel class of HSP90 pathway modulators. *Cancer Cell* *10*, 321–330.

- Huttlin, E.L., Jedrychowski, M.P., Elias, J.E., Goswami, T., Rad, R., Beausoleil, S.A., Villen, J., Haas, W., Sowa, M.E., and Gygi, S.P. (2010). A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* **143**, 1174–1189.
- Kadoch, C., Hargreaves, D.C., Hodges, C., Elias, L., Ho, L., Ranish, J., and Crabtree, G.R. (2013). Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. *Nat. Genet.* **45**, 592–601.
- Karolchik, D., Hinrichs, A.S., Furey, T.S., Roskin, K.M., Sugnet, C.W., Haussler, D., and Kent, W.J. (2004). The UCSC Table Browser data retrieval tool. *Nucleic Acids Res.* **32**, D493–D496.
- Kininis, M., and Kraus, W.L. (2008). A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. *Nucl. Recept. Signal.* **6**, e005.
- Koh, F.M., Lizama, C.O., Wong, P., Hawkins, J.S., Zovein, A.C., and Ramalho-Santos, M. (2015). Emergence of hematopoietic stem and progenitor cells involves a Chd1-dependent increase in total nascent transcription. *Proc. Natl. Acad. Sci. U S A* **112**, E1734–E1743.
- Kron, K.J., Murison, A., Zhou, S., Huang, V., Yamaguchi, T.N., Shiah, Y.J., Fraser, M., van der Kwast, T., Boutros, P.C., Bristow, R.G., and Lupien, M. (2017). TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. *Nat. Genet.* **49**, 1336–1345.
- Kumar, A., White, T.A., MacKenzie, A.P., Clegg, N., Lee, C., Dumpit, R.F., Coleman, I., Ng, S.B., Salipante, S.J., Rieder, M.J., et al. (2011). Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. *Proc. Natl. Acad. Sci. U S A* **108**, 17087–17092.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357–359.
- Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760.
- Litvinov, I.V., De Marzo, A.M., and Isaacs, J.T. (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? *J. Clin. Endocrinol. Metab.* **88**, 2972–2982.
- Liu, W., Lindberg, J., Sui, G., Luo, J., Egevad, L., Li, T., Xie, C., Wan, M., Kim, S.T., Wang, Z., et al. (2012). Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. *Oncogene* **31**, 3939–3948.
- Lotan, T.L., Torres, A., Zhang, M., Tosoian, J.J., Guedes, L.B., Fedor, H., Hicks, J., Ewing, C.M., Isaacs, S.D., Johng, D., et al. (2017). Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. *Oncotarget* **8**, 22772–22782.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550.
- Lusser, A., Urwin, D.L., and Kadonaga, J.T. (2005). Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. *Nat. Struct. Mol. Biol.* **12**, 160–166.
- Magee, J.A., Chang, L.W., Stormo, G.D., and Milbrandt, J. (2006). Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. *Endocrinology* **147**, 590–598.
- McNair, C., Xu, K., Mandigo, A.C., Benelli, M., Leiby, B., Rodrigues, D., Lindberg, J., Gronberg, H., Crespo, M., De Laere, B., et al. (2018). Differential impact of RB status on E2F1 reprogramming in human cancer. *J. Clin. Invest.* **128**, 341–358.
- Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., Li, T., Miteva, Y.V., Hauri, S., Sardi, M.E., Low, T.Y., et al. (2013). The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. *Nat. Methods* **10**, 730–736.
- Mohammed, H., Taylor, C., Brown, G.D., Papachristou, E.K., Carroll, J.S., and D'Santos, C.S. (2016). Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. *Nat. Protoc.* **11**, 316–326.
- Mooslehner, K.A., Davies, J.D., and Hughes, I.A. (2012). A cell model for conditional profiling of androgen-receptor-interacting proteins. *Int. J. Endocrinol.* **2012**, 381824.
- Moretini, S., Tribus, M., Zeilner, A., Sebald, J., Campo-Fernandez, B., Scheran, G., Worle, H., Podhraski, V., Fyodorov, D.V., and Lusser, A. (2011). The chromodomains of CHD1 are critical for enzymatic activity but less important for chromatin localization. *Nucleic Acids Res.* **39**, 3103–3115.
- Pauli, C., Hopkins, B.D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017). Personalized in vitro and in vivo cancer models to guide precision medicine. *Cancer Discov.* **7**, 462–477.
- Piatti, P., Lim, C.Y., Nat, R., Villunger, A., Geley, S., Shue, Y.T., Soratroi, C., Moser, M., and Lusser, A. (2015). Embryonic stem cell differentiation requires full length Chd1. *Sci. Rep.* **5**, 8007.
- Pomerantz, M.M., Li, F., Takeda, D.Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R.A., et al. (2015). The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. *Nat. Genet.* **47**, 1346–1351.
- Qin, Q., Mei, S., Wu, Q., Sun, H., Li, L., Taing, L., Chen, S., Li, F., Liu, T., Zang, C., et al. (2016). ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline. *BMC Bioinformatics* **17**, 404.
- Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842.
- Ramirez, F., Dundar, F., Diehl, S., Gruning, B.A., and Manke, T. (2014). DeepTools: a flexible platform for exploring deep-sequencing data. *Nucleic Acids Res.* **42**, W187–W191.
- Rappsilber, J., Ishihama, Y., and Mann, M. (2003). Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. *Anal. Chem.* **75**, 663–670.
- Roediger, J., Hessenkemper, W., Bartsch, S., Manvelyan, M., Huettner, S.S., Liehr, T., Esmaeili, M., Foller, S., Petersen, I., Grimm, M.O., and Baniahmad, A. (2014). Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. *Mol. Cancer* **13**, 214.
- Ross-Innes, C.S., Stark, R., Teschendorff, A.E., Holmes, K.A., Ali, H.R., Dunning, M.J., Brown, G.D., Gojis, O., Ellis, I.O., Green, A.R., et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature* **481**, 389–393.
- Shang, Y., Myers, M., and Brown, M. (2002). Formation of the androgen receptor transcription complex. *Mol. Cell* **9**, 601–610.
- Shen, H., and Laird, P.W. (2013). Interplay between the cancer genome and epigenome. *Cell* **153**, 38–55.
- Shenoy, T.R., Boysen, G., Wang, M.Y., Xu, Q.Z., Guo, W., Koh, F.M., Wang, C., Zhang, L.Z., Wang, Y., Gil, V., et al. (2017). CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. *Ann. Oncol.* **28**, 1495–1507.
- Shin, H., Liu, T., Manrai, A.K., and Liu, X.S. (2009). CEAS: cis-regulatory element annotation system. *Bioinformatics* **25**, 2605–2606.
- Siggens, L., Cordeddu, L., Ronnerblad, M., Lennartsson, A., and Ekwall, K. (2015). Transcription-coupled recruitment of human CHD1 and CHD2 influences chromatin accessibility and histone H3 and H3.3 occupancy at active chromatin regions. *Epigenetics Chromatin* **8**, 4.
- Simic, R., Lindstrom, D.L., Tran, H.G., Roinick, K.L., Costa, P.J., Johnson, A.D., Hartzog, G.A., and Arndt, K.M. (2003). Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes. *EMBO J.* **22**, 1846–1856.
- Sims, R.J., 3rd, Chen, C.F., Santos-Rosa, H., Kouzarides, T., Patel, S.S., and Reinberg, D. (2005). Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. *J. Biol. Chem.* **280**, 41789–41792.
- Skene, P.J., Hernandez, A.E., Groudine, M., and Henikoff, S. (2014). The nucleosomal barrier to promoter escape by RNA polymerase II is overcome by the chromatin remodeler Chd1. *eLife* **3**, e02042.
- Stelloo, S., Nevedomskaya, E., Kim, Y., Hoekman, L., Bleijerveld, O.B., Mirza, T., Wessels, L.F.A., van Weerden, W.M., Altelar, A.F.M., et al. (2018a). Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. *Oncogene* **37**, 313–322.
- Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., Krijgsman, O., Peeper, D.S., Chang, S.L., Feng, F.Y., et al. (2018b).

- Integrative epigenetic taxonomy of primary prostate cancer. *Nat. Commun.* **9**, 4900.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U S A* **102**, 15545–15550.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010). Integrative genomic profiling of human prostate cancer. *Cancer Cell* **18**, 11–22.
- Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Di Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., Van Dyke, T., et al. (2003). Pten dose dictates cancer progression in the prostate. *PLoS Biol.* **1**, E59.
- Wang, Q., Li, W., Liu, X.S., Carroll, J.S., Janne, O.A., Keeton, E.K., Chinnaiyan, A.M., Pienta, K.J., and Brown, M. (2007). A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. *Mol. Cell* **27**, 380–392.
- Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G.V., Li, G., Roy-Burman, P., Nelson, P.S., et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* **4**, 209–221.
- Wedge, D.C., Gundem, G., Mitchell, T., Woodcock, D.J., Martincorena, I., Ghorji, M., Zamora, J., Butler, A., Whitaker, H., Kote-Jarai, Z., et al. (2018). Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nat. Genet.* **50**, 682–692.
- Wu, X., Wu, J., Huang, J., Powell, W.C., Zhang, J., Matusik, R.J., Sangiorgi, F.O., Maxson, R.E., Sucov, H.M., and Roy-Burman, P. (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech. Dev.* **101**, 61–69.
- Zambelli, F., Pesole, G., and Pavesi, G. (2013). PscanChIP: finding over-represented transcription factor-binding site motifs and their correlations in sequences from ChIP-Seq experiments. *Nucleic Acids Res.* **41**, W535–W543.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-seq (MACS). *Genome Biol.* **9**, R137.
- Zhao, J.C., Fong, K.W., Jin, H.J., Yang, Y.A., Kim, J., and Yu, J. (2016). FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. *Oncogene* **35**, 4335–4344.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Alexa Fluor 488 Goat anti-mouse	Molecular Probes	Cat# A-11029, RRID:AB_138404
Alexa Fluor 555 Goat anti-rabbit	Thermo Fisher Scientific	Cat# A-21428, RRID:AB_2535849
alpha-Tubulin	Cell Signaling	Cat# 2144, RRID:AB_2210548)
Androgen Receptor	Abcam	Cat# ab108341, RRID:AB_10865716
Androgen Receptor	Abcam	Cat# ab74272, RRID:AB_1280747
Androgen Receptor	Abcam	Cat# ab9474, RRID:AB_307266
Androgen Receptor	Santa Cruz	Cat# sc-816, RRID:AB_1563391
anti-goat HRP	Thermo Fisher	Cat# 31402, RRID:AB_228395
anti-rabbit HRP	Pierce	Cat# 32260, RRID:AB_1965959
c-MYC	Santa Cruz	Cat# sc-764, RRID:AB_631276
CHD1	Bethyl	Cat# A301-218A, RRID:AB_890568
CHD1	Cell Signaling	Cat# 4351S, RRID:AB_11179073
H3K27me3	Abcam	Cat# ab195477
H3K4me2	Abcam	Cat# ab7766, RRID:AB_2560996
H3K4me3	Abcam	Cat# ab8580, RRID:AB_306649
HOXB13	Santa Cruz	Cat# sc-66923, RRID:AB_2233136
Lamin B	Santa Cruz	Cat# sc-6217, RRID:AB_648158
Mouse IgG	BioLegend	Cat# 400102
Rabbit IgG	Abcam	Cat# ab37415, RRID:AB_2631996
Vinculin	Abcam	Cat# ab129002, RRID:AB_11144129
Beta-actin	Fisher Scientific	PIMA515739
mKi67	Abcam	Cat# ab16667, RRID:AB_302459
CHD1	Active Motif	Cat# 39730
See Table S6 for detailed usage information		
Bacterial and Virus Strains		
Codon-improved Cre (iCre) and RFP Adenovirus	Vector Laboratories	1774
RFP Adenovirus	Vector Laboratories	1660
Chemicals, Peptides, and Recombinant Proteins		
5 α -Dihydrotestosterone (DHT) solution	Sigma-Aldrich	D-073-1ML
Enzalutamide (MDV3100) 10mg	Selleck Chemicals	S1250
Paraformaldehyde, 4% in PBS	VWR	AAJ61899-AK
Formaldehyde Ampules, Methanol-free - 10 x 1mL	Thermo Fisher Scientific	PI-28906
EGF Recombinant Mouse	Invitrogen	PMG8043
Primocin, 500 mg (10 x 1 ml tubes)	Invivogen	ant-pm-1
B-27™ Supplement (50X), serum free	Thermo Fisher Scientific	17504044
1M HEPES Solution	Thermo Fisher Scientific	15630080
GlutaMAX™ Supplement	Thermo Fisher Scientific	35050061
Y-27632 2HCl (Rock I inhibitor)	Selleck Chemicals	S1049
LightCycler® 480 SYBR Green I Master	Roche	04887352001
Nonidet P40 Substitute	Sigma-Aldrich	11332473001
Triton™ X-100	Sigma-Aldrich	T8787-100ML

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
AMPure XP beads	Beckman Coulter	A63881
Dynabeads® Protein A for Immunoprecipitation	Thermo Fisher Scientific	10002D
Xfect™ Transfection Reagent	Clontech	631318
Proteinase K Solution (20 mg/mL)	Thermo Fisher Scientific	AM2548
RNase A, DNase and protease-free (10 mg/mL)	Thermo Fisher Scientific	EN0531
Trypsin from porcine pancreas	Millipore Sigma	T6567-5X20UG
Poly-L-lysine hydrobromide	Sigma-Aldrich	P1274-25MG
Matrigel Matrix GFR PhenolRF Mouse	VWR	47743-722 (BD 356231)
Testosterone pellets (15 mg)	Innovative Research of America	A-151
Prolong Gold Antifade with DAPI	ThermoFisher	P36931
Critical Commercial Assays		
KAPA Hyper Prep Kit (Illumina, 24 rxns)	Kapa Biosystems	KK8502
Library Quantification Kit - Illumina/ LightCycler® 480	Kapa Biosystems	KK4854
iBlot™ 2 Transfer Stacks, nitrocellulose, mini	Thermo Fisher Scientific	IB23002
Maxwell 16 LEV simplyRNA Cells Kit	Promega	AS1270
High Sensitivity DNA Analysis Kits	Agilent Technologies	5067-4626
Qubit™ dsDNA HS Assay Kit	Thermo Fisher Scientific	Q32854
Duolink PLA Kit	Sigma Aldrich	DUO92101
TruSeq RNA Library Prep Kit v2	Illumina	RS-122-2001
Deposited Data		
RNA-Seq	GEO	GSE117429
ChIP-Seq	GEO	GSE117430
Mass-Spec	PRIDE	PXD010468
ATAC-Seq	GEO	GSE123333
Experimental Models: Cell Lines		
LNCaP	ATCC	CRL-1740
C57BL/6 murine prostate organoids	This paper	
Experimental Models: Organisms/Strains		
Mouse C57BL/6 <i>Chd1^{tm1c(KOMP)Rsan}</i>	Jackson Labs	Guzman-Ayala et al., 2015
Mouse C57BL/6 Tg(Pbsn-cre)4Prb/J	Jackson Labs	Trotman et al., 2003 ; Wang et al., 2003
Mouse C57BL/6 C;129S4-Ptentm1Hwu/J	Jackson Labs	Trotman et al., 2003 ; Wang et al., 2003
Oligonucleotides		
NimbleGen SeqCap Adapter Kit A	Roche	07 141 530 001
See Table S5 for a detailed primer list		
Recombinant DNA		
pReceiver-M13-C-Flag-Human-HOXB13-orf	GeneCopoeia	EX-M0909-M13
Empty control vector for pReceiver-M03	GeneCopoeia	EX-NEG-M03
All-In-One pLentiCRISPR v2/ sgRNA_nontargeting_human	GenScript	
All-In-One pLentiCRISPR v2/ CHD1 CRISPR guide RNA 1	GenScript	ACCCAGAATCATCATCCGAC
All-In-One pLentiCRISPR v2/ CHD1 CRISPR guide RNA 2	GenScript	TTCTGATCCGCTATTAGATG

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Software and Algorithms		
FastQC- Version 0.11.7	N/A	https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
Bowtie2 (v2.2.9)	Langmead et al., 2012	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Samtools (v1.7)	Li and Durbin, 2009	http://samtools.sourceforge.net/
DeepTools (v3.0)	Ramirez et al., 2014	https://deeptools.readthedocs.io/en/develop/
MACS2	Zhang et al., 2008	https://github.com/taoliu/MACS
Bedtools	Quinlan and Hall, 2010	https://github.com/arq5x/bedtools2
Diffbind (v3.7)	Ross-Innes et al., 2012	https://rdrr.io/bioc/DiffBind/
Homer (v4.8.3)	Heinz et al., 2010	http://homer.ucsd.edu/homer/download.html
pScan	Zambelli et al., 2013	http://159.149.160.88/pscan/
CEAS (v1.0.2)	Shin et al., 2009	https://anaconda.org/bioconda/ceas
STAR (v2.4.0j)	Dobin et al., 2013	https://github.com/Kingsford-Group/ribomap
RSEQtools (v2.1)	Habegger et al., 2011	http://rseqtools.gersteinlab.org/
HTSeq	Anders et al., 2015	https://github.com/simon-anders/htseq
GSEA	Subramanian et al., 2005	http://software.broadinstitute.org/gsea/index.jsp
DESeq2 (v1.20.0)	Love et al., 2014	https://bioconductor.org/packages/release/bioc/html/DESeq2.html
SEQUEST (v28 revision 13)	ThermoFisher	
Crapome	Mellacheruvu et al., 2013	https://www.crapome.org/
Pscan	Zambelli et al., 2013	http://159.149.160.88/pscan/
Prism	Commercial	https://www.graphpad.com/scientific-software/prism/
Other		
Fetal Bovine Serum (U.S.), Charcoal/ Dextran Treated	Hyclone	SH30068.03HI

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Christopher E. Barbieri (chb9074@med.cornell.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse Breeding, Genotyping, and Tissue Processing

All mouse studies were approved by Weill Cornell Medicine (WCM) Institutional Care and Use Committee under protocol 2015-0022. *Chd1-Exon16^{-ff}* mice were previously published (Guzman-Ayala et al., 2015) and were obtained from the Jackson Laboratories repository (strain *Chd1^{tm1c(KOMP)Rsan}*). For prostate-specific deletion of *Chd1* alone or in combination with *Pten*, *Chd1^{ff}* mice were crossed with the previously described *Pb-Cre4;Pten^{ff/+}* mice (Trotman et al., 2003; Wang et al., 2003). Only *Pb-Cre4*-positive male mice were used for *Pb-Cre4* crosses. All described mice are in a C57BL/6 background. Genotyping was performed and confirmed by TransNetYX. Whole murine prostates were micro-dissected from mice at the indicated age, imaged, weighed, and then fixed overnight in 4% PFA. Sections were then transferred to 70% EtOH solution and paraffin embedded, sectioned, and stained by the Weill Cornell Medicine Translational Research Program Core. For genotyping primers see Table S5.

Murine Organoid Generation and Growth

Prostates from the mice of the given genotype were harvested between 3-4 months of age and processed and grown as previously described (Drost et al., 2016) to generate both 3D and 2D organoid cultures. Where applicable, removal of the floxed allele was achieved through transient viral infection of 2D organoids using adenoviral expressing CRE or empty vector (Vector Labs Cat #1774 and 1660). After 72 hr, cells were propagated in 3D or 2D culture and assessed for CHD1 loss via immunoblot and IF.

Murine Pathology Review

All sections were reviewed by a board-certified genitourinary pathologist with expertise in human and murine models of prostate cancer (B.D.R). Reviews were performed blinded to age and genotype.

Human Cell Lines

LNCaP cells were purchased from the American Type Culture Collection (ATCC- Item # CRL-1740), grown on poly-L-lysine coated plates in 5% Fetal Bovine Serum (FBS) containing RPMI-1640, and incubated at 37°C and 5% CO₂. Cells were passaged twice weekly or once cultures reached 80% confluency. All 2D and 3D cultures were assessed for mycoplasma monthly via the highly sensitive PCR based kit from ABM (Cat #ABM G238). Where applicable, cell line identity was validated yearly through the Human STR profiling cell authentication service provided by ATCC.

CRISPR Model Generation

LNCaP cells (< passage 15) were transfected with All-In-One pLentiCRISPR v2/sgRNA plasmids containing either control or *CHD1* specific sgRNAs (ACCCAGAATCATCATCCGAC or TTCTGATCCGCTATTAGATG) purchased from GenScript. Cells were selected with puromycin until resistant populations emerged, and then assayed for CHD1 expression via immunoblot.

Transient Models

LNCaP cells were transfected with Ctrl or Flag-HOXB13 expressing constructs (GeneCopoeia Cat# EX-M0909-M13, EX-NEG-M03) using the Xfect transfection system (Clontech Cat # 631317). Six hr post transfection, cells were plated in 96 well plates and assed for growth using Incucyte Zoom technology.

METHOD DETAILS

Murine Castration-Testosterone Re-Supplementation

Mice of the given genotypes were aged to 3-4 months before surgical castration. Two weeks post castration, 15 mg testosterone pellets (A-151 Innovative Research of America) were implanted subcutaneously into all mice and prostates harvested for analysis 2 weeks thereafter.

Immunofluorescence

Cells were plated and grown on coverslips for 48-72 hr then fixed for 15 min with 4% PFA at room temperature. Cells were washed twice with PBS and then permeabilized with 0.1% Triton-X100 in PBS for 10 min. Following an additional PBS wash, cells were blocked with 10% goat serum and 0.5% BSA in PBS for 30 min at room temperature. Primary antibody was applied at the specified dilution in blocking solution overnight at 4°C. The following morning, cells were washed twice with PBS and incubated with the appropriate fluorescent secondary antibody (in blocking solution) for 30 min in the dark. Coverslips were then washed three times with PBS, mounted with Prolong Gold antifade mount solution with DAPI (Thermofisher Cat # P36931), and visualized using a fluorescent microscope.

Growth Assays

Five thousand cells were plated in a 96 well plate in phenol-red free RPMI-1640 containing 5% charcoal dextran treated serum (CDT). Cells were allowed to attach overnight and were treated with varying concentrations of DHT (in EtOH). Growth was monitored and calculated using Incucyte software. The average of 4 images per well were plotted in biological triplicate for each cell line and each condition.

ChIP and ChIP Sequencing

LNCaP cells were grown in RPMI-1640 supplemented with 5% FBS and stimulated with 10 nM DHT for 3 hr. Twenty million cells per replicate were fixed using 1% formaldehyde for 10 min at 24°C, quenched for 5 min with 0.125 M glycine, and stored at -80°C until use. Samples were thawed on ice and processed for ChIP as previously described (McNair et al., 2018). Briefly, fixed pellets were lysed in 1% SDS lysis buffer and sonicated for 27 cycles (30s on/off) in a temperature controlled Bioruptor 300 to obtain a size range of 250-400 bp. Samples were spun at 15000 RPM for 20 min to remove debris, and individual samples were incubated with Protein A/antibody conjugated beads overnight rocking at 4°C. Samples were washed 6 times with increasing salt buffers and DNA eluted at 65°C overnight. All samples were treated with RNase A for 30 min at 37°C followed by Proteinase K at 65°C for 1 hr. DNA was purified using phenol chloroform and individual ChIP samples were verified by q-PCR. ChIP sequencing libraries (20 ng DNA per sample) were constructed using the KAPA Hyper Prep Kit (Illumina-Kapa biosystems Cat # KK8502, NimbleGen SeqCap Adapter Kit A- Roche Cat # 07 141 530 001) according to the manufacturer's instructions. Libraries were assessed for quality, purity, and size using DNA High Sensitivity Bioanalyzer chips (Agilent Technology Cat #5067-4626), and libraries passing quality control (equal size distribution between 250-400 bp, no adapter contamination peaks, no degradation peaks) were quantified using the Library Quantification Kit from Illumina (Kapa Biosystems KK4854). Libraries were pooled to a final concentration of 10nM and sequenced using the Illumina HiSeq 4000.

Quantitative PCR

Quantitative PCR (Q-PCR) was performed using 4% of purified ChIP DNA per reaction. Reactions were conducted in technical triplicate and quantified as previously described (Augello et al., 2013). Standard error was calculated for each locus and condition, with statistical differences defined as $p < 0.05$ using a student's T test within Prism software. For primer details see Table S5.

Immunoblot

Cells were harvested under the described conditions and lysed in RIPA buffer. 20–30 μg of total cell lysate were loaded onto polyacrylamide gels, transferred to nitro-cellulose membranes, and probed for the indicated targets as previously described (Augello et al., 2013). For antibody use and details see Table S6.

Chromatin Tethering

Isogenic models of *CHD1* loss were processed for AR tethered chromatin under androgen proficient conditions as previously described (Augello et al., 2013). Briefly, 250000 cells were washed with Buffer A and lysed with 100 μL of Buffer B on ice. Cells were then spun at 20000 RPM for 30 min to isolate soluble from chromatin fractions. Chromatin fractions were resuspended in 200 μL of Buffer B/1x SDS-lysis buffer, with soluble fractions diluted to 200 μL using the same buffer. All samples were sonicated in a Bioruptor 3000 for 5 cycles on high (30s on/off) and boiled at 100°C for 5 min. Samples were then run on a polyacrylamide gel for analysis.

Xenograft Studies

6–8 weeks old athymic nude male mice were subcutaneously injected on the flank with 2 million cells suspended in a 1:1 ratio of PBS to Matrigel in a volume of 100 μL . Tumors were monitored for growth twice weekly, and volume measured using electronic calipers. Mice were sacrificed 2 months post-injection, or when the tumor reached 800 mm^3 .

Growth Curves

Isogenic cell line models were plated in phenol red-free RPMI-1640 supplemented with 5% charcoal dextran treated (CDT) serum (Hyclone Cat # SH30068.03HI) (7000 cells per well in a 96 well plate). Cells were allowed to attach overnight and subsequently treated with increasing concentrations of DHT or 0.1% vehicle (EtOH). Treatments were conducted in biological triplicate and proliferation over time was monitored and calculated using IncuCyte Zoom technology/software.

Proximity Ligation Assay

LNCaP cells were grown on Poly-L-Lysine coated coverslips in androgen proficient, or androgen deficient conditions for 72 hr. Cells were then fixed and permeabilized as per the immunofluorescence protocol above. PLA was then carried out using the Duolink PLA kit (Sigma Aldrich Cat# DUO92101) following the manufacturer's instructions and the indicated antibodies (Table S6). Nine images were taken for each PLA condition at 20x and 40x magnification in a single plane. Signal was then quantified for each image at 20x magnification using Image J software.

QUANTIFICATION AND STATISTICAL ANALYSIS

ChIP Sequencing Analysis

Human cell line reads (FASTQ files) were validated for quality using FastQC software (Version 0.11.7), and single end reads with a score > 29 were aligned to the hg19 human reference genome using Bowtie2 (v2.2.9) software (default parameters). SAM files were converted to BAM format, sorted, PCR duplicates removed, ENCODE blacklist regions removed, and final BAM files indexed using Samtools software (v1.7). Duplicate BAM files were combined to generate RPKM normalized bigwig files for each factor using Deeptools (v3.0) (Ramirez et al., 2014) which were then used to generate subsequent heatmaps and binding profiles (Deeptools v3.0). Previously aligned and normalized bigwig files from Pomerantz et. al. (Pomerantz et al., 2015) and Kron et al. (Kron et al., 2017) were downloaded and analyzed in their published format. H3K27ac dataset utilized only ERG negative tumors as to avoid driver effects specific to this subclass. When applicable, NCBI RefSeq gene annotation and locations were downloaded from the USCS genome browser (Karolchik et al., 2004), and assessed for factor binding enrichment using Deeptools (v3.0). Multiple transcriptional start sites were collapsed prior to analysis.

Peak Calling

Peaks were called using MACS2 (Zhang et al., 2008) with a p value $< 10^{-8}$ or $q = 0.05$ (replicates combined) using the narrow peak caller for all datasets except H3K27me3 which used the broad calling option with $q = 0.1$. Peak overlap and Venn diagrams were generated using pybedtools and bedtools intersect function (Quinlan and Hall, 2010) and was defined as overlap ≥ 1 bp. Differential peak calling was determined from 2 biological replicates using the Diffbind R package (v3.7) with peak calls for individual replicates from MACS2 using $q = 0.05$, an FDR = 0.01, and the EdgeR default settings as previously described (Stark et al., 2011, Bioconductor).

Motif Analysis

Motif analysis was conducted using Homer v4.8.3 (Heinz et al., 2010) using a 200 bp window around the center of each peak. Motif density around peaks was calculated using Homer and JASPER definitions of the conserved motif. To determine motif enrichment between datasets with similar peak numbers, peak sets of the control were used as background (-bg flag in findmotifsgenome.pl function). For analyses where the number of peaks differed greatly between conditions, 20000 peaks were randomly selected using bedtools sample function and assessed for known JASPER motif enrichment using Homer software (annotatepeaks.pl) run 100 times for each condition/replicate. For enhancer specific assessment of motif enrichment, peaks localized to promoters/TSS were removed prior to analysis. Where indicated, motif enrichment was validated using pScan (default parameters) (Zambelli et al., 2013). Unless otherwise noted, significant motif enrichment was considered only if the p value was $\leq 10^{-20}$.

Motif Analysis of Primary Human Prostate Tumors

Copy number analysis of primary human prostate cancers for the *CHD1* locus was performed as described in (Stelloo et al., 2018b). AR peaks from these tumors (Stelloo et al., 2018b) were binned into *CHD1* deficient (homozygous and heterozygous deletions) and *CHD1* WT. ERG high tumors were eliminated from this analysis to avoid observations driven by the dominant ERG signal. Thirteen *CHD1* deficient and 17 *CHD1* WT tumors (minimum 1000 peaks) were utilized for motif enrichment. Peaks from each genotype were merged to generate *CHD1* null and *CHD1* WT peak sets. Differential *de novo* motif analysis was determined for each peak set using the opposing dataset as background using Homer software (v4.1.0) findmotifsgenome.pl function (-bg flag) using the hg19 genome build and a 200 bp window flanking the center of each peak.

Genomic Region Annotation

Cis-regulatory element analysis was performed using CEAS v1.0.2 (Shin et al., 2009) in conjunction with the Homer annotatepeaks.pl function and the hg19 genome annotation.

ATAC Seq

LNCaP isogenic models of *CHD1* loss were starved of androgen for 72 hr and treated with either vehicle (0.1% EtOH) or DHT (10 nM) for 4 hr. Cells were then fixed using 4% PFA, washed in PBS 2x, and 50000 cells/condition were submitted in biological duplicate to the Dana Farber Center for Functional Cancer Epigenetics for ATAC Seq library preparation, sequencing, processing, and analysis using the Omni-ATAC protocol as previously described (Corces et al., 2017). Briefly, 10^5 cells were resuspended in 1 mL of cold ATAC-seq resuspension buffer (RSB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl, and 3 mM MgCl₂ in water). Cells were centrifuged at 500 g for 5 min in a pre-chilled (4°C) fixed-angle centrifuge, and the supernatant was carefully aspirated. Cell pellets were resuspended in 50 μ L RSB containing 0.1% NP40, 0.1% Tween-20, and 0.01% digitonin by pipetting up and down three times. Cell lysis reaction was incubated on ice for 3 min. After lysis, 1 mL RSB containing 0.1% Tween-20 (without NP40 or digitonin) was added, and the tubes were inverted to mix. Nuclei were then centrifuged for 10 min at 500 g in a pre-chilled fixed-angle centrifuge. Supernatant was removed and nuclei were resuspended in 50 μ L of transposition mix (Corces et al., 2017) (2.5 μ L transposase26 (100 nM final), 16.5 μ L PBS, 0.5 μ L 1% digitonin, 0.5 μ L 10% Tween-20, and 5 μ L water) by pipetting up and down six times. Transposition reactions were incubated at 37°C for 30 min in a thermomixer with shaking at 1000 rpm. Reactions were cleaned up with QIAquick PCR spin columns. Library quantitation and number of amplification cycles was determined as described (Buenrostro et al., 2015). After sequencing on a NextSeq 500 per manufacturer instructions, ChiLin pipeline 2.0.0 was used for quality control and pre-processing (Qin et al., 2016). This includes Burrows-Wheeler Aligner (BWA) for read mapping (Li and Durbin, 2009), Model-based Analysis of ChIP-Seq (MACS) as a peak caller (Zhang et al., 2008), and DESeq2 for differential peak analysis (Love et al., 2014). For ATAC peak motif enrichment, peak sets between replicates were merged prior to analysis.

RNA-seq Analysis

Growth Conditions- Isogenic LNCaP cells were grown in androgen deprived media for 72 hr and then stimulated with 1 nM DHT (or vehicle) for 3 and 8 hr in biological triplicate. Murine organoids were grown in 2D in complete prostate organoid media for 48 hr and harvested for RNA in biological triplicate. Human cell lines and mouse organoids were prepared for RNA sequencing using TruSeq RNA Library Preparation Kit v2. RNA integrity was verified using the Agilent Bioanalyzer 2100 (Agilent Technologies). Cell lines samples were then sequenced with the HiSeq 2500 to generate 2 \times 51-bp paired-end reads, and organoids samples were sequenced with 2 \times 151-bp paired-end reads. Human cell line reads (FASTQ files) were mapped to the human reference genome sequence (hg19) using STAR v2.4.0j (Dobin et al., 2013), and mouse organoid reads were mapped to the mouse reference genome sequence (mm10). The resulting BAM files were subsequently converted into mapped-read format (MRF) using RSEQtools (v2.1) (Habegger et al., 2011). The read count of each gene was calculated via HTSeq (Anders et al., 2015) using GENCODE as reference gene annotation set. Quantification of gene expression was performed via RSEQtools (v2.1), and expression levels (RPKM) were estimated by counting all nucleotides mapped to each gene and were normalized by the total number of mapped nucleotides (per million) and the gene length (per kb). The genomic status and AR output score of TCGA samples were downloaded from TCGA study (Cancer Genome Atlas Research Network, 2015). The AR output score of our samples were calculated by following the similar strategy as TCGA study (Cancer Genome Atlas Research Network, 2015). Specifically, the AR output score was derived from the mRNA expression of 20 genes that were experimentally validated AR transcriptional targets from LNCaP cell line (Hieronymus et al., 2006). Here the Z-score for the expression of each gene in each sample was calculated and the AR score for each sample was then computed as the

sum of the Z-scores of 20 AR signaling genes. Heatmap and hierarchical clustering were performed via using correlation distance and Ward's method. GSEA (Subramanian et al., 2005) was performed using JAVA program and run in pre-ranked mode to identify enriched signatures. We used the gene sets in the Molecular Signature Database (MSigDB) (Subramanian et al., 2005). The GSEA plot, normalized enrichment score and q-values were derived from GSEA output for each MSigDB hallmark signature. Differentially expression analyses were performed using DESeq2 (v1.20.0) (Love et al., 2014) based on the gene read count data. Multiple-hypothesis testing was considered by using Benjamini-Hochberg (BH; FDR) correction. The *CHD1* null AR signature from the LNCaP isogenic model of *CHD1* loss was generated by first defining all differentially expressed genes in the sgCHD1 line between vehicle and 8 hr DHT treatment using an FDR of 0.01. These androgen regulated genes were then assessed for changes between the sgCtrl and sgCHD1 lines at the 8 hr DHT timepoint using an adjusted p value of 0.05 as a significance threshold.

Generation of *CHD1* Null Transcriptional Signature from TCGA

By following a similar strategy (Blattner et al., 2017), we developed the *CHD1* deletion transcriptional signature that included 282 genes differentially expressed between *CHD1* deleted and WT samples from TCGA prostate cancer RNA-seq data. The low-expressed genes (mean RSEM < 1) were filtered prior to analysis. Specifically, we identified significantly differentially expressed genes by comparing *CHD1* deletion and WT cases as determined from genomic analyses among TCGA samples lacking ETS family gene fusions (*ERG*, *ETV1*, *ETV4* and *FLI1*), using Wilcoxon rank-sum test and controlled for false discovery using Benjamini-Hochberg adjustment ($FDR \leq 1 \times 10^{-5}$). Heatmap and hierarchical clustering were performed via using correlation distance and Ward's method on TCGA and LNCaP model.

RIME Analysis

Cells were prepared as per the ChIP protocol above and processed for RIME as previously described (Mohammed et al., 2016). Peptides were desalted on hand-packed C18 STAGE tip columns (Rappsilber et al., 2003). Eluted peptides were dried down in a centrifugal evaporator, reconstituted in 5% formic acid and analyzed by nanospray LC-MS/MS on an Orbitrap Fusion mass spectrometer (ThermoFisher). Peptides were separated by reverse-phase HPLC on a hand-packed column (packed with 40 cm of 1.8 μ m, 120 Å pores, Sepax GP-C18, Sepax Technologies, Newark, DE) using a 85 min gradient of 5–27% buffer B (ACN, 0.1% FA) at a 350 nL/min. Peptides were detected using a Top20 method. For each cycle, one full MS scan of $m/z = 375$ –1400 was acquired in the Orbitrap at a resolution of 120000 at m/z with AGC target = 5×10^5 . Each full scan was followed by the selection of up to 20 of the most intense ions for CID and MS/MS analysis in the linear ion trap. Selected ions were excluded from further analysis for 30 s. Ions with charge 1⁺ or unassigned were also rejected. Maximum ion accumulation times were 100 ms for each full MS scan and 35 ms for MS/MS scans.

MS2 spectra were searched using SEQUEST (v28 revision 13) against a composite database containing all Swiss-Prot reviewed human protein sequences (20193 target sequences downloaded from www.uniprot.org on March 18, 2016) and their reversed complement, using the following parameters: a precursor mass tolerance of ± 20 ppm; 1.0 Da product ion mass tolerance; tryptic digestion; up to two missed cleavages; static modifications of carbamidomethylation on cysteine (+57.0214), and a dynamic modification of methionine oxidation (+15.9949). Peptide spectral matches were filtered to 1% FDR using the target-decoy strategy (Elias and Gygi, 2007) combined with linear discriminant analysis (LDA) using SEQUEST scoring parameters including Xcorr, $\Delta Cn'$, precursor mass error, and charge state (Huttlin et al., 2010).

Two independent biological replicates were processed for each IP, the log signal to noise ratios (S/N) from IgG samples were subtracted from each IP condition, and those with a score > 0.2 and a minimum of 6 peptides between replicates were included for further processing. These data were then analyzed using the Crapome database with isotype matched IgG and Crapome controls (Mella-chervu et al., 2013), and only peptides with a SAINT score > 0.9 (out of 1) were included in downstream analyses.

Ki67 Quantification

Three independent, representative images were taken at 20x magnification for each mouse prostate. The percentage of Ki67 positive epithelial cells was calculated for each image (at least 500 total cells per image) and the mean and standard error of all images for each genotype was determined. Normal distribution of the data were confirmed using D'Agostino-Pearson omnibus normality test, prior to a student's 2-sided t-test which was used to determine statistical differences between the two genotypes. For the castration-restimulation experiments, Ki67 counts are representative of differences observed in the anterior prostate gland.

Tumor-Xenograft Volume Quantification

Volume for each xenograft was calculated using electronic calipers ($w \times l \times h - \text{mm}^3$) and plotted 10 weeks post-injection. The difference in the mean volume between xenograft lines was determined using a 2-sided students t-test (p value = 0.803).

Xenograft-Tumor Take Quantification

Formation of palpable tumor formation was performed twice weekly and reported for each xenograft line. Tumor-free survival was calculated using both the logrank Mantel-Cox and Gehan-Breslow-Wilcoxon test. Curves were not statistically different using either test with p values of 0.61 and 0.82, respectively.

PLA Quantification

A minimum of 75 cells per condition were quantified in a single plane for detectable foci using image J. The number of foci per cell per condition is reported. Differences in the mean number of foci between conditions was determined using One-way ANOVA and Turkey's multiple comparisons test.

Growth Curves

Biological triplicates for each cell line and condition were assessed for confluency using Incucyte software every 4 hr for the indicated duration. The mean and standard error of each time point is plotted. Differences in growth in response DHT/enzalutamide were determined via EC50 calculations 100 hr post treatment. The individual biological triplicates (and calculated standard error) for each dose and cell line were used as input, and differences in EC50 calculated using non-linear regression software, least squared (ordinary) fit, and the Extra sum-of-squares F test (p value < 0.05) to determine statistical differences between EC50 values.

String Analyses

Peptides significantly enriched in the CHD1 RIME dataset were analyzed for overlap with that of the previously identified AR RIME interactome (Stelloo et al., 2018a). Common proteins were uploaded to the STRING database (STRING-db.org v10.5) and assessed for potential direct and indirect interactions.

DATA AND SOFTWARE AVAILABILITY

RNA-Seq data has been deposited in GEO under the accession GSE117429.

ChIP-Seq data has been deposited in GEO under the accession GSE117430.

Mass-Spec data has been deposited in PRIDE under the accession PXD010468.

ATAC-Seq data has been deposited in GEO under the accession GSE123333.